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ABSTRACT 
ABSTRACT 
Periprosthetic joint infection (PJI) is a severe complication to hip and knee 
arthroplasty surgery. In the light of its devastating implications for the affected 
patient, its great economic impact on the health care system and the increasing 
antimicrobial resistance, it is important to develop efficient diagnostic 
methods, identify optimal treatment pathways and improve the care for 
patients.  
Using a microbiological approach, Paper I aimed to identify the impact of 
biofilm production and susceptibility on clinical outcome. The result showed 
a greater risk of persisting PJI in patients infected by strong biofilm producing 
staphylococci compared to non- or weak biofilm producers, suggesting the 
implementation of biofilm diagnostics in clinical routine. Paper II aimed to 
compare two surgical techniques of DAIR (debridement, antibiotics and 
implant retention) treatment using a register-based approach. The superiority 
of modular component exchange compared to non-exchange was established 
and the exchange of modular components should be employed in cases where 
DAIR is a viable option. In terms of implant extracting treatment, Paper III 
aimed to identify re-revision rates after one- and two stage revision procedures 
using a national register. No difference in re-revision rates were observed, 
supporting the use of the one-stage procedure which is a more economic choice 
and more lenient alternative for patients. Paper IV aimed to investigate the 
experiences and emotional impact of PJI on surgeons using qualitative 
analysis. The results confirm a negative emotional impact in surgeons 
and highlight the importance of multidisciplinary work and inter-collegial 
support for optimal PJI management and for the wellbeing of surgeons. 
Keywords: arthroplasty surgery, periprosthetic joint infection, biofilm 
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SAMMANFATTNING 
SAMMANFATTNING PÅ SVENSKA 
 
Protesinfektion är en svår komplikation efter höft- och knäproteskirurgi. För 
drabbade patienter är den förenad med stort fysiskt och psykiskt lidande men 
innebär också höga samhällskostnader i form av sjukvård, hemvård och 
arbetsfrånvaro. Under 2018 opererades cirka 19 000 höftproteser och 15 000 
knäproteser i Sverige. Protesinfektion kan vara svårt att fastställa men 
uppträder hos cirka 1% av patienter. Eftersom befolkningen blir allt äldre 
kommer efterfrågan av proteskirurgi sannolikt att öka inom nära framtid. 
Därmed förväntas också protesinfektioner bli ett större problem också med 
tanke på den ökande antibiotikaresistensen hos bakterier.  
 
Trots ett ökat forskningsintresse de senaste åren saknas det tillräckligt med 
vetenskapligt belägg för hur man på bästa sätt ska diagnostisera, behandla och 
förhindra protesinfektioner. Behandlingen innebär oftast kirurgi där man 
spolar rent och/eller ersätter de infekterade protesdelarna. Samtidigt behandlas 
patienten med antibiotika under längre tid, ibland flera månader, för att 
bekämpa infektionen. Det finns flera sätt att lägga upp behandlingen på. Ofta 
anpassas och påverkas den av flera faktorer såsom typ av infektion samt 
patientens och kirurgens preferenser. Dessvärre leder inte all behandling till att 
infektionen läker ut. Ibland får patienten genomgå ett flertal 
behandlingsomgångar med antibiotikakurer och operationer vilket leder till 
umbäranden för patienten. I vissa fall läker infektionen inte ut utan att protesen 
behöver tas bort permanent och i sällsynta fall måste benet amputeras. 
Protesinfektion är förknippat med en ökad dödlighet. 
 
Studierna i den här avhandlingen syftar till att förbättra kunskapen om olika 
aspekter av protesinfektioner genom att utvärdera sjukdomsbildande 
egenskaper hos bakterier i relation till infektionsutläkning, olika kirurgiska 
behandlingsmetoder samt att kartlägga och bättre förstå proteskirurgers 
erfarenheter och upplevelser av arbetet med protesinfektioner. 
 
För att utvärdera sjukdomsbildande egenskaper hos bakterier, har vi studerat 
bakterier som är tagna under operationer för höft- och knäprotesinfektioner 
(studie I). Dessa bakterier har sedan analyserats avseende sin förmåga att bilda 
en hinna på protesen och omkringliggande vävnad, så kallad biofilm, som 
skyddar dem från kroppens immunförsvar och gör dem svåråtkomliga för 
antibiotikabehandling. Biofilmen tros vara en anledning till att vissa bakterier 
blir svårare att bekämpa. I vår studie kunde vi se att bakterier i biofilm är 
mycket tåliga mot antibiotika och att infektioner orsakade av starka 
biofilmsproducerande bakterier har en högre risk för att inte läka utan 
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SAMMANFATTNING 
upprepade operationer. Att mäta biofilm ingår inte i rutindiagnostik men skulle 
kunna vara fördelaktigt för att på ett tidigt stadium kunna lägga upp ett bättre 
behandlingsförfarande. 
 
Det finns olika kirurgiska behandlingsmetoder för protesinfektioner. Överlag 
visar forskning att man uppnår bäst resultat med metoder där man byter ut hela 
protesen. Detta förfarande innebär dock stora påfrestningar för patienten och 
är också dyrt varför man ofta prövar alternativ behandling. En sådan möjlighet 
är en ”DAIR” operation. Det innebär att man spolar och noggrant rengör 
protesen samt omkringliggande vävnad och ofta byter ut utbytbara icke-
benförankrade delar av protesen. De flesta studier angående 
behandlingseffekten av DAIR-metoden omfattar ett begränsat antal patienter. 
Därför valde vi att studera behandlingsmetoden DAIR via ett nationellt register 
(Svenska Höftprotesregistret) där protesoperationer registreras samt 
komplettera data med hjälp av insamlat journalmaterial (studie II). Vi fann att 
DAIR, med byte av protesdelar, är en överlägsen metod och bör användas i 
möjligaste mån. 
 
När DAIR inte anses vara ett alternativ byts hela protesen ut, antingen under 
en och samma operation (en-seans-operation) eller att protesen tas bort vid ett 
tillfälle och när infektionen sedan anses utläkt sätts en ny protes in vid ett annat 
tillfälle (två-seansrevision). Traditionellt har två-seansrevision mestadels 
använts då man trott att detta gett bättre chans till utläkning. Däremot är 
perioden däremellan utan protes, påfrestande för patienten. Det är också dyrare 
med två operationstillfällen varför en-seansrevision är önskvärt. Under de 
senaste åren har forskning inte kunnat påvisa någon större skillnad i 
infektionsutläkning mellan dessa operationsmetoder. Vi jämförde dem med 
hjälp av Svenska Höftprotesregistret och fann inte någon skillnad (studie III). 
Fyndet stödjer användandet av en-seansrevision, även om mer forskning krävs 
för att bekräfta den slutsatsen. 
 
Mot bakgrund av att protesinfektioner orsakar stort lidande för patienter och 
kan vara svåra att behandla valde vi att göra en intervjustudie om 
protesoperatörens erfarenheter och känslomässiga påverkan av protesinfektion 
(studie IV). Vi fann att dessa infektioner hade en negativ känslomässig 
påverkan med stora skuldkänslor hos operatören. Operatörerna upplevde att 
det var extra viktigt med stöd från kollegor liksom samarbete, inte minst med 
infektionsläkare. Denna studie belyser medarbetarperspektivet och ger en 
bättre förståelse för operatörens komplexa situation. Den identifierar också 
förbättringsområden för att underlätta situationen för både patient och 
behandlande läkare. Vi hoppas att förståelsen för de svårigheter som 
protesinfektioner innebär skall öka, och leda till att arbetet med 
protesinfektioner förbättras.
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1 PROLOGUE 
At the time of writing, I am a first-year orthopaedic resident and alongside 
trying to familiarise with surgical manuals, fracture management and trying 
to find my favourite implant, this thesis project has kept me rather occupied 
for the past few years. As a medical student I had the opportunity to work in 
the arthroplasty ward at Mölndal’s hospital which is where I had my first 
encounter with patients suffering from periprosthetic joint infections. It had 
a deep impact on me. Some of these patients were in the ward throughout 
my three-month placement, pending from hope to despair. I met one patient 
on a daily basis and witnessed the mental and physical withering of this 
person first-hand. This patient had suffered of mobility pain for several years 
and had been over the moon after undergoing arthroplasty surgery. Finally 
pain free. Only to be struck by an infection some weeks later. An 
infection that after some years of struggling with repeated surgery, 
antibiotic treatment, long periods of hospitalisations, mental distress and 
further physical disability, led to this patient’s passing. 
Originally, I had been very interested in sports medicine, having a career as 
an athlete (and as a patient!) behind me. However, my encounters at 
the arthroplasty ward changed my focus. A while later the projects of this 
thesis started taking form, much thanks to the help of Henrik Malchau, 
Johan Kärrholm, Ola Rolfson and Maziar Mohaddes who further introduced 
me to Margarita Trobos and Annette Erichsen Andersson. 
There is yet a lot to be done within this research field and my hope is that the 
results of this thesis may contribute to the improvement in care of patients, 
and raise awareness of the complexity of periprosthetic joint infections  
and the associated problems that they entail.  
Thank you to everyone who has made this thesis possible and who has 
been with me on this journey! 
DEFINITIONS 
II 
’ 
“Your life is destroyed, absolutely destroyed. 
There is nothing you can do. You lose your 
privacy. You lose your dignity. You lose your 
independence. You have no life. For someone like 
me who lived a very physically—and I’m a very 
gregarious person, I would have happily—in fact 
I would have happily ended it all. I stood at the 
top of the stairs many times and thought, “If I 
just went, could I guarantee that this would get 
me out of this?” because it was that desperate, 
and I’m a very strong person.”  
Maggie	in	Moore	et	al.1
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2 INTRODUCTION 
Treatment with orthopaedic implants such as hip and knee arthroplasties has 
improved the quality of life for patients with degenerative joint diseases. In 
Sweden, 18,629 primary total hip arthroplasties (THA) and 15,430 total knee 
arthroplasties (TKA) were performed in 2018.2, 3 Complications after 
arthroplasty surgery include aseptic loosening of the implant, periprosthetic 
fractures, dislocation and infection.2 Periprosthetic joint infection (PJI) is the 
most common cause of reoperation and typically appears within two years after 
primary surgery.2, 4 PJI is a devastating complication that induces a great level 
of patient suffering.1, 5, 6 Although relatively low, PJI is associated with 
mortality rates of 2.2-3.5%.7, 8  In addition, it leads to high healthcare and 
societal costs due to various factors such as prolonged hospital stays, further 
surgical procedures and home care.9-13  
Incidence rates of PJI after TKA and THA are elusive, but have been reported 
at around 0.89 to 2.3%.4, 10, 14-17 During the past years an increase in revision 
procedures due to infection has been observed in the Nordic countries,4, 18 and 
increased incidence of PJI has been projected in non-Nordic countries.19-21 The 
increase in revision procedures may suggest an actual increasing incidence of 
infection.22 The increasing incidence of infection may also be due to other 
factors such as enhanced diagnostic methods enabling a higher rate of accurate 
diagnoses. In contrast, there is also research suggesting a plateaue,23 and 
decline in infection incidence.16 At the same time, the numbers of THA and 
TKA are expected to increase in the coming decades due to an increasing 
elderly population rendering in greater demands for total joint arthroplasty.24,
25 Therefore, regardless of the projections for PJI incidence, the absolute 
number of PJI cases is expected to increase. In parallel with the emerging 
antimicrobial resistance (AMR) and development of difficult-to-treat 
pathogens, PJI may become a greater problem in the near future. A higher 
incidence and poor treatment outcomes along with a global increase in 
antibiotic resistance, which by 2050 is estimated to cause more annual deaths 
than cancer,26, 27 stresses the need for research efforts within infection control. 
In summary, it is of importance to recognize all the economic, societal and 
individual implications that PJI has in order to address preventative measures, 
improve treatment efficacy and care. Thankfully, PJI has gained a lot of 
attention during the past years. In Sweden, an initiative called PRISS 
(Prosthetic Joint Infections Shall Be Stopped) started in 2009 to increase 
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 3 
awareness of PJI nationwide and establish guidelines based on current 
evidence. Globally, the initiative of Professors Thomas Gehrke and Javad 
Parvizi has led to an international consensus meeting (ICM) on orthopaedic 
infections, where multiple aspects of PJI are discussed in an evidence-based 
manner using the Delphi method in an attempt to reach consensus.28 
Thankfully, the research interest for PJI has increased greatly the past years 
(Figure 1), and this thesis aims to add on to the ongoing work on some of the 
aspects of PJI of the hip and knee using variable approaches. 
Figure 1. The increase in publications on PJI from the years 1969 to 2019 in the 
PubMed database. 
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2.1 AETIOLOGY 
“Nobody	knew	where	the	infection	had	come	from...I	hadn’t	had	any	broken	skin.	I	hadn’t	
had	an	accident	of	any	form,	I	had	no	viral	problems	of	any	sort.”	
Patient	Rory	(Moore	et	al.1)	
There are several known routes of contamination for PJI. Infection sources can 
be either endogenous or exogenous. Endogenous spread of infection is when 
microorganisms present in the patient’s normal flora, e.g. on the patient’s skin, 
enter the sterile environments of the muscle tissue and joint capsule. In PJI, 
this type of spread can occur whenever there is a skin opening, such as during 
surgery or postoperatively during the healing of the wound.29 Another 
endogenous route is the haematogenous spread of infection where bacteria 
present in the blood stream spread to the prosthesis and surrounding 
tissue. Exogenous sources of infection involve external bacteria that do not 
reside in the normal flora of the patient. Exogenous bacteria can enter the 
patient’s body through particles from the air in the operating room 
(OR), contaminated surgical equipment or healthcare staff.  
Linnéa Teljas Puranen 
Figure 2. The microbial contamination route can be either endogenous such as via the 
blood stream or the patient’s normal skin flora, or exogenous such as via air particles, 
contaminated surgical equipment or healthcare personnel. 
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The aetiology of PJI is multifactorial and the possible contributing causes such 
as the pathogen’s virulence, patient-related factors, peri-operative risk factors, 
and implant-related aspects will be discussed in this chapter. However, firstly, 
a distinction between the terms related to timing of infection will be made. 
Early infection is regarded as symptom onset within three months of receiving 
an implant.30 Early infections may be caused perioperatively, either by 
endogenous, or exogenous bacteria in the OR or hospital ward. Up to 90% of 
PJI are classified as early infections making it the most common presentation.31 
Late infection is defined as symptom onset after three months of receiving an 
implant.30 The onset of late PJI may be the result of low virulent bacteria or a 
haematogenous spread.  
Both early and late infections can be either acute or chronic (Figure 3). Early 
acute or late acute symptom onset implies an acutely swollen, red and painful 
joint, sometimes together with sepsis. Patients with early chronic onset present 
with persisting wound leakage, whereas late chronic infections are associated 
with chronic pain, sometimes with a sinus tract or signs of loosening on X-
rays.30 The definitions of timing of infection vary, e.g. Zimmerli et al. suggest 
that early infection occurs within two months of surgery, delayed infection 
three to 24 months after surgery, and late after two years.32 Acute infections 
are suggested to be caused by highly virulent microbes compared to chronic 
infections which are caused by low-virulent pathogens.33  
Figure 3. Classification of infection onset as suggested by Barrett et al.30 
 
2.1.1 Bacterial pathogenicity and virulence 
 
In Europe, the two most common causative pathogens of PJI of hip and knee 
are Staphylococcus aureus (S. aureus) and coagulase-negative staphylococci 
(CoNS),15, 34-38 followed by Escherichia coli, enterococci, Cutibacterium acnes 
(C. acnes) and streptococci.39, 40 The microbial profile may differ depending 
on if the infection is early onset, late onset or haematogenous spread. 
Staphylococcus aureus is the most common pathogen in early onset,41 while 
CoNS are more common in late onset41 (with the exception of haematogenous 
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origin in which S. aureus dominates32).36 In the present thesis, the main focus 
will be on staphylococci as they are the most common cause of PJI.  
For staphylococci, the ability to colonise an implant surface and the severity 
of the infection depends on the expression of virulence factors. Staphylococci 
involved in the pathogenesis of PJI display several virulence factors such as 
production of toxins, adhesion factors and immune evasion proteins.41 The 
pathogenic factors vary by species and S. aureus is known as a highly virulent 
species associated with several pathogenic mechanisms.41, 42 One such is its 
ability to persist intracellularly in host cells.43 Staphylococcus epidermidis, a 
CoNS, is not recognized as equally virulent as S. aureus and produces less 
pathogenic toxins than S. aureus. However, S. epidermidis carries determinants 
promoting persistence such as immune evasion molecules and can transfer its 
genes to enhance the pathogenicity of S. aureus.44 Both CoNS and S. aureus 
can form biofilm which is a virulence factor considered of great importance 
within medical device-related infections, such as PJI. 
Features of the bacterial biofilm 
The mode of growth of bacteria can either be planktonic i.e. in their free-
floating single-cell form, or they can form a biofilm and grow in multi-cellular 
communities. Biomaterial-associated infections (BAI) are believed to be 
caused by bacteria growing as biofilms on implants or surrounding tissues.45 
Two-thirds of BAIs are caused by S. aureus and S. epidermidis.46  
The biofilm is a gel-like substance composed of cells and self-produced 
extracellular polymeric substances (EPS) such as proteins, polysaccharides 
and extracellular DNA.45, 47, 48 It has several properties contributing to its 
recalcitrance such as its viscoelasticity, heterogeneity (composed of clusters of 
communicating cell communities i.e. microcolonies) and increased tolerance 
to the host immune response and antimicrobials despite being susceptible as 
planktonic cells.49, 50 In addition, bacteria in biofilms have special 
characteristics making them more recalcitrant in comparison to planktonic 
infections.45, 49-51 Examples of such characteristics are: 
• Adhesion mechanisms.
• The aggregation in self-produced EPS which serves as a
protector for the bacterial cells.
• A slowed metabolic activity leading to slow-growing
bacterial colonies consisting of inactive dormant cells and
small-colony variants, which are more tolerant to
antimicrobial agents.
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• A capability of inter-cellular communication via quorum 
sensing which regulates the expression of virulence genes in 
response to fluctuations in cell-population density. 
 
Figure 4.  Scanning electron microscopy (SEM) of Staphyoloccocus epidermidis 
biofilm grown on a titanium screw. Image taken by Sara Svensson. 
 
The pathogenesis of a biofilm 
 
In an orthopaedic context, the bacterial cells adhere to orthopaedic implants 
and surrounding tissue and form biofilm.52 There is no universal biofilm 
mechanism and there are differences among the mechanisms that induce 
biofilm formation in diverse bacterial species. Simplified, in staphylococci, the 
biofilm life cycle consists of four steps: adherence, accumulation, maturation 
and dispersal (Figure 5).41, 47   
 
1. Adherence  
Physiochemical interactions (phase 1, reversible):  Bacteria first adhere to the 
material surface by hydrophobic, van der Waals and electrostatic forces.47 
These are reversible interactions.  
 
Molecular and cellular interactions (phase 2, irreversible): Then bacteria 
initiate specific adherence interactions between their adhesins (autolysins, 
Microbial Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs) and the host extracellular matrix (ECM).47At first, the 
adherence of the planktonic cells is reversible, and the bacteria are yet 
2 INTRODUCTION 
 6 
origin in which S. aureus dominates32).36 In the present thesis, the main focus 
will be on staphylococci as they are the most common cause of PJI.  
For staphylococci, the ability to colonise an implant surface and the severity 
of the infection depends on the expression of virulence factors. Staphylococci 
involved in the pathogenesis of PJI display several virulence factors such as 
production of toxins, adhesion factors and immune evasion proteins.41 The 
pathogenic factors vary by species and S. aureus is known as a highly virulent 
species associated with several pathogenic mechanisms.41, 42 One such is its 
ability to persist intracellularly in host cells.43 Staphylococcus epidermidis, a 
CoNS, is not recognized as equally virulent as S. aureus and produces less 
pathogenic toxins than S. aureus. However, S. epidermidis carries determinants 
promoting persistence such as immune evasion molecules and can transfer its 
genes to enhance the pathogenicity of S. aureus.44 Both CoNS and S. aureus 
can form biofilm which is a virulence factor considered of great importance 
within medical device-related infections, such as PJI. 
Features of the bacterial biofilm 
The mode of growth of bacteria can either be planktonic i.e. in their free-
floating single-cell form, or they can form a biofilm and grow in multi-cellular 
communities. Biomaterial-associated infections (BAI) are believed to be 
caused by bacteria growing as biofilms on implants or surrounding tissues.45 
Two-thirds of BAIs are caused by S. aureus and S. epidermidis.46  
The biofilm is a gel-like substance composed of cells and self-produced 
extracellular polymeric substances (EPS) such as proteins, polysaccharides 
and extracellular DNA.45, 47, 48 It has several properties contributing to its 
recalcitrance such as its viscoelasticity, heterogeneity (composed of clusters of 
communicating cell communities i.e. microcolonies) and increased tolerance 
to the host immune response and antimicrobials despite being susceptible as 
planktonic cells.49, 50 In addition, bacteria in biofilms have special 
characteristics making them more recalcitrant in comparison to planktonic 
infections.45, 49-51 Examples of such characteristics are: 
• Adhesion mechanisms.
• The aggregation in self-produced EPS which serves as a
protector for the bacterial cells.
• A slowed metabolic activity leading to slow-growing
bacterial colonies consisting of inactive dormant cells and
small-colony variants, which are more tolerant to
antimicrobial agents.
   2 INTRODUCTION 
 7 
• A capability of inter-cellular communication via quorum 
sensing which regulates the expression of virulence genes in 
response to fluctuations in cell-population density. 
 
Figure 4.  Scanning electron microscopy (SEM) of Staphyoloccocus epidermidis 
biofilm grown on a titanium screw. Image taken by Sara Svensson. 
 
The pathogenesis of a biofilm 
 
In an orthopaedic context, the bacterial cells adhere to orthopaedic implants 
and surrounding tissue and form biofilm.52 There is no universal biofilm 
mechanism and there are differences among the mechanisms that induce 
biofilm formation in diverse bacterial species. Simplified, in staphylococci, the 
biofilm life cycle consists of four steps: adherence, accumulation, maturation 
and dispersal (Figure 5).41, 47   
 
1. Adherence  
Physiochemical interactions (phase 1, reversible):  Bacteria first adhere to the 
material surface by hydrophobic, van der Waals and electrostatic forces.47 
These are reversible interactions.  
 
Molecular and cellular interactions (phase 2, irreversible): Then bacteria 
initiate specific adherence interactions between their adhesins (autolysins, 
Microbial Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs) and the host extracellular matrix (ECM).47At first, the 
adherence of the planktonic cells is reversible, and the bacteria are yet 
2 INTRODUCTION 
 8 
susceptible to antimicrobial agents, but at the end of this phase bacterial 
cells have attached to the surface irreversibly.50 Genes involved in the 
regulation of adhesion are suggested to be part of the accessory genome, 
thereby not a characteristic of all bacterial strains.47 
2. Accumulation
Once bacterial cells attach, they mediate intercellular adhesion via 
polysaccharide intercellular adhesin (PIA), accumulation associated proteins 
and eDNA to form a microcolony on the implant or the surround tissue and 
accumulate in layers.47 In this state, bacteria produce extracellular polymeric 
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spread and persistence of infection and is responsible for the septic loosening 
of an implant.47 
Bacteria in biofilms are less susceptible, by up to 51,200 
times, to antimicrobials than when in their planktonic state.56-58 In 
biofilms, bacteria have the ability to communicate with each other 
through quorum sensing enabling them to regulate their pathogenic 
factors and increase their AMR.32 The availability of nutrients and 
oxygen varies throughout the layers of the biofilm. The bacteria cells 
closest to the surface layer of the biofilm have greater access to 
nutrients and oxygen which is why they are metabolically active.59 In 
contrast, the bacterial cells in the deeper layers of the biofilm are the least 
active, so called persistent or dormant cells (Figure 6). The difference in the 
metabolic activity of the cells in the different layers of the biofilm is a 
contributor to AMR and important to consider in antimicrobial treatment. Also, 
the persistent or dormant cells are suggested to play an important role in 
the recalcitrance of biofilms in arthroplasty surgery.60 Furthermore, 
polymicrobial biofilms need to be considered as a threat to the 
success of antimicrobial therapy as several species may need targeting.49 
Linnéa Teljas Puranen 
Figure 6. In the biofilm, the metabolism of the layers differs. The superficial layer of 
bacterial cells is more metabolically active (orange bacteria) whereas the inner 
layers harbor fewer active cells, i.e. dormant or persistent bacteria (purple bacteria). 
2.1.2 Patient-related risk factors 
Several patient-related risk factors for PJI have been identified,28 and these 
should be considered prior to primary arthroplasty surgery. In accordance with 
the ICM documents, patient risk factors can be categorised as modifiable and 
non-modifiable (Table 1).28 Despite lacking evidence, modifiable risk factors 
should be optimised prior to surgery as a means to try and prevent PJI.61  
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Table 1. Modifiable and non-modifiable patient-related risk factors suggested by the ICM 
workgroup.28 
Modifiable risk factors Non-modifiable risk factors 
Active infection 
Alcoholism 
Cardiovascular disease 
Congestive heart failure 
Cardiac arrhythmia 
Chronic kidney disease 
Chronic obstructive pulmonary 
disorder 
Coagulation disorders 
Depression 
Diabetes  
Drug abuse 
Frailty 
HIV/AIDS 
Immunosuppression 
Intra-articular steroids 
Viscosupplementation 
Malnutrition 
MRSA/MSSA colonization 
Obesity 
Peripheral vascular disease 
Psychosis 
Rheumatoid arthritis 
Smoking 
Hepatitis C 
Age 
ASA > 2 
Bariatric surgery 
Chronic anticoagulation 
Gender 
Hemiplegia/paraplegia 
Hepatitis B 
Osteonecrosis 
Previous joint surgery 
Previous joint infection 
Previous infection 
Transplant 
In this thesis, the following patient risk factors have been obtained and 
evaluated: ASA-class (American Society of Anaesthesiologists 
Physical Status), age, body mass index (BMI), diabetes, sex, primary 
diagnosis for arthroplasty surgery and previous surgery.  
ASA-class 
The ASA-class is used by anaesthesiologists in clinical practice to determine 
which physical status the patient has pre-operatively (Table 2). This score can 
be used to evaluate the patient’s comorbidities. Several studies have 
unanimously reported on high ASA-class (defined as >2) as a risk factor for 
postoperative complications, including PJI.62-66  
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Table 2. The American Society of Anaesthesiologists Physical Status classification (ASA-class) 
and definitions. 
 
ASA- class Definition 
I Healthy 
II Mild systemic disease 
III Severe systemic disease 
IV Incapacitating disease 
V Moribund patient 
 
Age 
Age can be assumed a risk factor of PJI as the predisposition for infection 
increases with age due to various physiological changes i.e. a less active 
immune system and altered vascular conditions. However, for PJI, age is an 
ambiguous risk factor both associated,67 and not associated with it.18, 61, 68, 69  
 
BMI 
Patients with high BMI have a higher risk of PJI.61, 66, 68 There is no cut-off 
value for increasing BMI regarding increased risk of PJI.70 However, pooled 
data shows an increase in the relative risk of PJI with increasing BMI.61 
Patients with BMI > 40 kg/m2 have a higher risk,61 up to a threefold risk 
increase,71 of PJI and this is currently the cut-off value at which postponing 
surgery is recommended.28 Alongside associated comorbidities, obesity can 
impose a surgical difficulty expanding tissue exposure and the greater layer of 
low-vascular subcutaneous fatty tissue may impair wound healing.72 Further, 
obesity may increase surgical time which in turn may contribute to PJI. 
 
Research in underweight patients (<18.5 kg/ m2) and its effect on the risk of 
PJI is limited and controversial. Underweight compared to normal weight, has 
been reported as an independent risk factor for postoperative complications, 
whereof PJI was dominant.73 In contrast, underweight has not been associated 
with a greater risk for PJI.70  However, underweight and overweight could be 
confounders for malnutrition which in turn may increase the risk of PJI.74-76 To 
date, planned pre-operative weight loss, bariatric surgery, or weight gain have 
not been shown to affect the risk reduction of PJI.77, 78  
 
Diabetes 
Diabetes is a risk factor for PJI.61, 68, 79 In a study comparing patients with 
uncontrolled and controlled diabetes, patients with uncontrolled diabetes had 
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two times the risk of surgical site infection after arthroplasty surgery,80 
supporting the recommendations to optimize glycaemic control prior to 
surgery. Furthermore, it is important to maintain normoglycemic levels in both 
diabetic and non-diabetic patients during the peri-operative period to decrease 
the risk of infection. Patients undergoing orthopaedic surgery may develop a 
stress-induced hyperglycaemia which in turn has been associated to surgical 
site infection in orthopaedic surgery.81 
Sex 
Sex is an inconsistent risk factor of PJI. Female sex has been associated to a 
higher risk for surgical site infection subsequent THA,67 whereas several 
studies indicate male sex as a risk factor for revision due to PJI.18, 61, 66, 68, 69  
Primary diagnosis 
Patients with rheumatoid arthritis have a higher risk of PJI.69, 79, 82 However, 
due to new treatment possibilities for RA patients, treatment with arthroplasty 
surgery has become less common. Trauma as cause of a THA or TKA has also 
been associated with a greater risk for postoperative infection.67 Patients who 
receive a prosthesis due to a tumour have a greater risk of PJI, especially if 
they undergo chemotherapy.83  
Previous surgery 
Previous arthroplasty surgery in the affected joint increases the risk of PJI.61 
Patients who undergo revision arthroplasty have a higher rate of PJI, which 
may be due to compromised soft tissue and the risk of bacterial dissemination 
during revision surgery.29 Furthermore, patients who have had PJI and then 
receive a primary TKA in another joint have a greater risk of PJI.84 Although 
knowledge is scarce, patients who have undergone previous arthroscopy 
surgery have been reported being at greater risk of PJI.85 
2.1.3 Perioperative risk factors and preventive measures 
Although it is largely unknown how PJI arises, 80% are suggested to originate 
from the perioperative period and 20% from non-surgical factors.86 
Furthermore, surveillance of infection has proved successful in reducing the 
incidence of healthcare associated infections.87 This measure has not been 
studied in PJI, but may further strengthen the nosocomial origin of infections. 
Skin flora, constituting a bacterial reservoir, may contaminate the operating 
area and cause infection as the skin barrier is broken. Preoperative use of 
antiseptic applications, such as chlorhexidine, reduce the bacterial load on the 
patient’s skin, but need further evaluation due to small study sizes.28, 88-91  The 
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use of alcohol-based antiseptic applications is also recommended for 
perioperative surgical site preparation, but need further evaluation.28, 92 Plastic 
adhesive draping of the surgical site was introduced as an anti-infective 
measure, and although further evidence for its use in arthroplasty surgery is 
warranted, it has not been proven efficient in reducing contamination during 
other surgical procedures.93, 94  
A lot of focus is concentrated on the OR environment in regard of microbial 
contamination, often measured as viable colony-forming units (CFU) per m3. 
In the European Union, the World Health Organization state that the OR air 
should not exceed 10 CFU/m3 during orthopaedic surgery.95 However, little is 
known on how the number of CFU/m3 correlates to clinical outcome and it is 
not continuously registered or measured in a standardized way. 
The air cleanliness of an OR is a debated subject in terms of contamination and 
ultraclean ventilation systems are widely used in arthroplasty surgery.95 
Ultraclean ventilation implies the use of laminar airflow (LAF) and high-
efficiency particulate filters. LAF has been reported efficient in providing 
clean air in the OR and in reducing the number of CFU by 89% compared to 
air displacement systems.96 Previously, no benefit was established using  ORs 
with LAF to reduce PJI,18, 97 however, in 2020, Langvatn et al. proved a 
significant risk reduction of PJI when using LAF.98  
Many factors contribute to air cleanliness and these can be difficult to control 
in studies on airflow. There are no standard protocols for air measurement. 
Furthermore, the OR staff may constitute a source of contamination, despite 
hand wash, sterile clothing and the use of surgical masks. One study reported 
on the contamination of the OR and found that the same bacteria were present 
in the nasopharynx of OR staff.99 Observational data on contamination in the 
OR showed several actions and behavioral patterns of the OR staff increasing 
the risk for cross-contamination.100 These observations did not include the 
surgeon’s behavior but the activities of other members of the OR staff such as 
when inserting an intravenous catheter or during respiratory intubation. Other 
factors contributing to air contamination in the OR may be the number of 
people present and the number of door openings.101 
Furthermore, surgeons believe that surgery duration is a risk factor of 
PJI102, and long duration of surgery,67 of more than 100 minutes,18, 103, 104 has 
been associated with an increased risk for PJI. The risk of PJI is suggested to 
increase by 9% for every 15 minutes of surgery.65 However, surgeon work 
experience does not seem to affect the risk for PJI in studies on TKA.65, 66  
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2.1.4 Implant related factors and implant surfaces 
Race for the surface 
Host cells and bacterial cells can both compete for the colonization of the 
surface of a newly implanted prosthesis. This was defined as “race-for-the-
surface" by Gristina in 1987 describing the first steps of a pathogenic process 
involving bacteria and host cells and their ability to adhere to, and compete 
for the colonisation of, an exogenous surface.105 If the race is won by tissue 
cells then the implant surface is less susceptible to biofilm formation. 
However, if the implant surface is colonized by bacteria, tissue cell functions 
are hindered by bacterial virulence factors.  
As described in the previous section, microorganisms are frequently 
introduced on an implant surface during surgery, getting a head start on the 
race for the surface, before tissue integration is established.105 Further, the 
presence of a foreign material, such as a prosthesis, reduces the pathogen’s 
inoculum size needed for infection establishment. In an animal model, with 
and without implant, contamination of 50 bacteria resulted in infection 
compared to 10 000 bacteria, respectively.106  
After the implantation of a prosthesis, there is an accumulation of granulocytes 
around the prosthesis. It is suggested that the granulocytes become impaired 
and that this may contribute to the possibility for local bacterial spread on the 
implant.107 As previously indicated, bacteria are attracted to the material 
surface by hydrophobic, van der Waals and electrostatic forces and can 
thereafter colonise the implant.47, 105 The physiochemical properties of an 
implant surface is an important factor in the pathogenesis of medical device-
related infection. In vitro and in vivo studies have reported on differences in 
bacterial adhesion and biofilm formation depending on the physiochemical 
properties of the biomaterial surface.108, 109  
Anti-infective surfaces 
Creating antimicrobial surfaces is an important part of infection prevention. 
However, the optimal anti-infective implant surface needs to meet several 
requirements: good biocompatibility, mechanical properties withstanding 
stress intra- and postoperatively with an established and durable anti-infective 
effect.110 Preventing bacterial adhesion using hydrophilic polymer coatings is 
one such strategy, however, such materials may compromise the non-
adherence of host cells which may be problematic for osseointegration.109, 111  
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Metallic coatings of implants have been tested, and a combination of gold, 
silver and palladium has been reported to promote osseointegration and reduce 
bacterial adhesion.112 Another coating strategy is attracting host cells for tissue 
integration prior to bacterial adhesion. This strategy is based on “the race for 
the surface” and in orthopaedics it involves coating implants with 
hydroxyapatite. Further strategies could be the use of resorbable hydrogel 
coatings of the implant loaded with antimicrobial agents,113 or the addition of 
vitamin E in resorbable coating materials as a measure to reduce bacterial 
adhesion whilst avoiding toxicity of chemical compounds.114 Another method 
of antimicrobial delivery may be its incorporation in polyethylene.115  
 
Linnéa Teljas Puranen/Karin Svensson 
 
Figure 7. The properties of an optimal prosthesis surface are biocompatibility (A), 
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The use of a spacer (a temporary implant) is another method for local 
antimicrobial delivery during treatment of PJI (Figure 8). Spacers can be 
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handmade, prefabricated or custom molded. For patients who undergo two-
stage revision (page 24), the use of spacers is debated, but may improve 
mobility,119 alongside having an anti-infective purpose if loaded with 
antimicrobial agents. However, spacers can cause pain,119 and lead to 
complications such as dislocation and fractures.120 
 
Figure 8. A hip cement spacer mold. Image kindly provided by Lars Ek at Zimmer 
Biomet. 
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2.2 DETECTION AND DIAGNOSIS 
“You wouldn’t have thought you would have got an infection after five years [...] 
Out of the blue, that’s what I can’t understand.”	
Patient	Jim	(Moore	et	al.	1) 
Linnéa Teljas Puranen 
Figure 9. Common symptoms of PJI are persistent wound leakage (patient to the left), 
pain (patient in the middle), erythema and fever (patient to the right). 
The most common symptoms of PJI are pain, persistent wound leakage, 
erythema and fever (Figure 9).5, 31 Although these symptoms are associated 
with PJI it can be difficult to detect and diagnose PJI, impeding the 
confirmation of diagnosis. PJI does not always present in a typical way. Pain, 
without any further objective signs of PJI, is sometimes the only symptom a 
patient presents with. In late chronic PJI, secondary radiographical signs of 
bone remodeling may appear, or the development of a sinus tract.  
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Figure 10. Patients with PJI may present with typical symptoms such as local 
erythema, wound leakage and purulence (as shown in the photo) or diffuse symptoms 
such as pain with no objective signs of infection. An atypical presentation can imply 
difficulties in detection and diagnosis.  Photo used with the permission of Ola Rolfson. 
 
Thus, due to atypical symptoms PJI should be ruled out in cases of dislocation 
and aseptic loosening. In studies investigating the final diagnosis of patients 
initially diagnosed with aseptic loosening, 8-12% turned out to have PJI.121, 122 
 
Yet another difficulty may be the absence of objective signs such as elevated 
inflammatory markers. It is recommended that C-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR) should be measured in patients with 
suspected PJI.123 However, these inflammatory markers are not specific and 
may even not be elevated in cases of low virulent PJI. 
2.2.1 Diagnostic criteria 
 
Several attempts have been made to define the diagnostic criteria of PJI. The 
most recent was developed by Parvizi et al. and is referred to as the 2018 
Musculoskeletal Infection Society (MSIS) criteria and has a sensitivity of 
97.7% and specificity of 99.5% (Table 3).124 However, this algorithm is not 
fully adopted by the orthopaedic community,28 but is widely used in research.  
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Table 3. Diagnostic criteria as proposed by Parvizi et al.124 
Note: *If the minor criteria are inconclusive, intraoperative criteria can be used.  
**If the intraoperative criteria are inconclusive, the authors suggest the consideration of molecular 
diagnostics. 
CRP=C-reactive protein, D-dimer=fibrin degradation product, ESR=erythrocyte sedimentation rate, 
WBC=white blood cell count, LE=leukocyte esterase, PMN=polymorphonuclear leukocytes 
In a clinical setting, the number of positive culture samples for one species can 
be interpreted differently depending on the type of species present. In cases 
where there is growth of a possible contaminant species such as C. acnes or 
CoNS, more than one positive culture with the same organism is needed. In 
cases where a highly virulent bacteria such as S. aureus is retrieved, one 
positive sample may be enough to confirm PJI.123 Furthermore, PJI can be 
diagnosed if a single positive culture from tissue samples shows identical 
bacterial species growth to that of a pre-operative joint aspiration.123 
2.2.2 Verifying the diagnosis 
Verifying the diagnosis may be difficult as certain circumstances may obstruct 
the ability for representative sampling. Some patients receive pre-operative 
systemic, or local, antimicrobial treatment which may lead to false-
negative results. It is therefore recommended, if possible, that patients stay 
off systemic antimicrobial treatment at least two weeks prior to pre-
operative or intra-operative testing, if possible.125  
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Pre-operative testing 
 
An arthrocentesis is recommended in patients prior to surgery if symptoms 
allow for it.123, 126 Joint aspirations should be analysed for a total cell count, 
white blood cell (WBC) count, and both aerobic and anaerobic bacterial 
culturing.123 Aspirations of synovial fluid may be inconclusive as bacterial 
aggregates may not be captured in samples.127  
 
Intra-operative tissue sampling 
 
Intra-operative tissue sampling is regarded the “gold standard” for PJI 
verification.128 In Sweden, intraoperative histopathological examination with 
direct microscopy is not conducted. All tissue samples are sent to a clinical 
laboratory for further analyses. Five intra-operative tissue samples are 
recommended to optimize the chance for diagnosis,123, 129 however, there is 
evidence suggesting that four samples may be sufficient.37  
 
The type of tissue sample may affect the rate of positive cultures. Sampling of 
joint fluid and surrounding tissue in contact with prosthetic material are the 
best providing 90% true culture positivity.37 Further, large samples up to 1 cm3 
are recommended.126 Using a mix of culture media (Schaedler broth, chocolate 
agar, and a blood culture bottle) can reduce the number of culture media needed 
whilst upholding diagnostic efficacy.37  
 
Time to culture positivity is dependent on culture media, type of bacteria and 
bacteria susceptibility.37, 129 Kheir et al. reported that a majority of bacterial 
strains (98%) are culture positive within eight days,129 but others, such as C. 
acnes, take up to 14 days to grow.129, 130 However, for aerobic bacteria, time to 
growth can be reduced to 24h depending on culture media.37 Resistant bacterial 
strains, bacteria isolated in acute infections, and bacteria with high virulence 
are associated with a higher frequency of culture-positive results.128, 129 
  
Sonication is suggested as a mean to increase the sensitivity for diagnosis as 
the use of an ultrasound apparatus dislodges bacterial cells from their 
biofilm.126, 131 Sonication has been reported to have a higher sensitivity and 
specificity than standard tissue culture.121, 131 However, the largest existing 
study reports on higher sensitivity when using standard tissue culturing 
compared to sonication.128 Culture positivity is lower in patients with pre-
operative antimicrobial treatment compared to without.132 Further, it is 
important to have a routine for how culture samples are handled and 
transported. Prolonged transportation time may affect culture results.125 
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Radiological and nuclear medical verification 
The use of radiological methods may aid in the diagnosis of PJI. Plain 
radiographs can reveal gas formation, immature periostitis and signs of 
prosthetic loosening.125 Furthermore, computed tomography (CT) scanning 
may also be useful as signs of joint distension and fluid collection in soft tissue 
can be evaluated with this technique. Ultrasound imaging can detect fluid 
around the prosthesis, and although not specific for PJI these findings can 
contribute to strengthening the suspicion of infection.125 Other radiological and 
nuclear medical methods with diagnostic value in PJI include different types 
of scintigraphy, magnetic resonance imaging (MRI), positron emission 
tomography with the use of a glucose analogue (FDG-PET) and hybrid single-
photon emission computed tomography (SPECT)/CT. 
2.2.3 Microbiological methods to facilitate treatment choice 
Minimum inhibitory concentration 
The minimum inhibitory concentration (MIC) is the lowest concentration of an 
antimicrobial agent at which visible growth of planktonic bacteria in vitro is 
inhibited. In clinical practice MIC is used as the standard microbiological 
guidance for antimicrobial treatment. Susceptibility is determined using pre-
defined clinical breakpoints for the microbe and antimicrobial agent.  The 
European Committee on Antimicrobial Susceptibility Testing 
(EAUCAST) is an organisation that defines clinical breakpoints.133 In this 
thesis, susceptibility categories are used in accordance with the EUCAST 
clinical breakpoints for staphylococci (Appendix, Supplementary Table 1).133  
As MIC is defined for planktonic bacteria it may be insufficient as a 
treatment guide for bacteria in biofilm-associated infections. Bacteria in 
biofilm are often reported to be less susceptible to antimicrobial agents, 
sometimes requiring antimicrobial concentrations up to 51,200 times higher 
than the MIC.56, 57, 134 
Minimum biofilm eradication concentration 
The minimum biofilm eradication concentration (MBEC) is the lowest 
concentration of an antimicrobial agent needed to eradicate a biofilm in vitro. 
Currently there are no methods used for determining biofilm production and 
biofilm susceptibility in clinical practice. There are suggestions on the use of 
clinical markers for biofilm production such as the quantification of eDNA 
(extracellular DNA) produced by S. epidermidis,135 and the use of MBEC. 
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MBEC can be determined in vitro using a Calgary Biofilm Device (CBD). This 
method is mainly used in research and is described in Paper I.   
Recently, Zaborowska et al. investigated the biofilm production and MBEC in 
bacteria isolated from infected percutaneous orthopaedic implants.58 Although 
not of statistical significance due to the sample size of the study, they observed 
that bacteria with higher biofilm production were more common in patients 
with worse clinical outcome. In their study, seven of eleven patients 
experienced treatment failure. Of the seven, six displayed high MBECs for the 
administered antimicrobial treatment. 
Using a biomarker such as MBEC to identify biofilm production and 
susceptibility may facilitate the choice of treatment. Guiding antimicrobial 
treatment using MBEC may be difficult as it may imply toxic effects. 
However, MBEC could guide antimicrobial treatment by empirically giving a 
notion on whether the bacteria may be difficult to treat. In such cases, surgical 
treatment may be directed differently to be more radical. So far, little is known 
about any correlation between biofilm production and the clinical outcome in 
PJI and if MBEC is correlated to biofilm production. 
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2.3 TREATMENT 
 
PJI is often treated with a combination of surgery and antimicrobial therapy. 
The surgical treatment aims at removing infected tissue to achieve vital 
vascular tissue and mechanically disrupting biofilm. There are different types 
of surgical methods and the most common will be described in the next section.  
2.3.1 Surgical methods 
 
In this section the most common surgical methods and current 
recommendations will be described. Surgical treatment aims at eradicating the 
infection by either preserving or extracting the infected implant (entire 
prosthesis or modular components). This section focuses on the hip as the 
papers of this thesis mainly involve THA. However, the principles are the same 
for infected TKA. 
 
A total hip prosthesis generally consists of bone-anchored components (the 
femoral stem and the acetabular cup) and of modular components (femoral 
head and acetabular polyethylene or ceramic liner) (Figure 11). The acetabular 
liner is not always modular, as is the case for most cemented cups. In this 
thesis, hip implant preserving surgery is defined as any procedure in which the 
femoral stem and acetabular cup have not been replaced. Implant extracting 
procedures are all types of procedures where the bone-anchored components 
i.e. the acetabular cup and/or femoral stem are exchanged or extracted.  
 
 
 
 
Karin Svensson 
 
Figure 11. The components of a hip implant. A total hip prosthesis consists of the 
femoral stem (A), femoral head (B), liner (C) and acetabular cup (D).  
A 
B 
C 
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Implant preserving surgery  
 
Implant preserving surgery can be conducted as a DAIR procedure 
(Debridement, Antibiotics and Implant Retention). A DAIR procedure can be 
performed in two different ways, either with or without an exchange of 
modular components (Figure 12A and B, respectively).  
 
Although there are no clear indications for DAIR, it is mainly recommended 
for early acute infections,123 and for acute hematogenous infections.136 Since a 
successful DAIR is advantageous from a patient and cost perspective,10, 40 it is 
desirable to identify which patients benefit from it, and how it should be 
performed. Reports on the success rates of DAIR vary from 27%-87%.10, 15, 34, 
40, 137-141 However, it should be noted that many studies are of a small sample 
size.142 Also, the vast range in success rates can be explained by a heterogeneity 
in study designs and outcome definitions (Table 4). 
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Figure 12. DAIR with debridement and irrigation but no exchange of modular 
components (A) and DAIR with debridement, irrigation and the exchange of modular 
components, in this case an exchange of the femoral head (B). 
A 
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Table 4. The differences in definitions and success rates in recent studies on the 
DAIR procedure. 
Study Success 
rate 
Population Follow-
up 
Time from 
index surgery 
Definition of 
success 
Kamp et al. 
201915 
87% 236 
(THA, TKA) 
1 yr <90 days Infection free 
Jacobs et al. 
201934* 
85% 91 
(THA, TKA) 
1 yr <90 days Infection free 
Löwik et al. 
2019138** 
62% 769 
(THA, TKA) 
1 yr <12 weeks No further 
surgery 
Grammatapoulus 
et al. 201740 
67% 
(single 
DAIR) 
85% 
(multiple 
DAIR) 
122 
(THA) 
M 7 yrs <13 weeks Separate 
definitions for 
single and 
multiple 
DAIR 
Uriarte et al. 
2019141 
27% 26 
(THA) 
>1 yr <3 months No further 
surgery or AB 
yr= year, AB=antibacterial treatment, THA=total hip arthroplasty, TKA=total knee arthroplasty, M=mean 
*=Patients with negative culture growth were included, multiple DAIR allowed.
**=Revision THA included in study cohort. 
Many factors may need consideration when choosing DAIR.137 Timing is one 
such factor. DAIR is recommended within four weeks from previous 
surgery.123 However, there is reason to believe that it may be beneficial in 
patients with longer time to symptom onset, up to 90 days,40, 138 and that timing 
may not correlate with failure.34 DAIR has also proved most successful when 
conducted as soon as symptoms arise, and some studies recommend its use 
within 7 days of symptom onset.39, 136, 137 Thresholds are yet to be determined 
for optimal timing of DAIR in relation to symptoms. 
Knowing the causative microorganism has been argued as desirable when 
proceeding with a DAIR.28 Jacobs et al. found a higher failure rate when the 
infection was caused by Enterococcus faecalis.34 Staphylococcus aureus has 
also been associated with higher failure,8 and streptococcal infection has been 
associated with both better and worse outcomes when using DAIR.40, 140 
However, to date, there is not enough evidence to support a delay of DAIR 
until culture growth is known.136  
The exchange of modular components is associated with greater success than  
a non-exchange.8, 40, 136, 137, 140 However, this evidence is based on smaller study 
samples. In a meta-analysis of 1296 PJI patients exchanging components in 
THA had a mean success rate of 74% compared to no exchange at 61%.137 
Previous surgery such as multiple DAIRs, is associated with a higher failure 
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rate.34 The experience of the surgeon conducting DAIR may also affect results, 
with an experienced hip surgeon having a better success rate.141 
Implant extracting surgery 
Implant revision surgery is most often conducted in chronic infections and in 
patients where DAIR has been unsuccessful. In patients with late acute 
infections (>3 months after previous surgery) , implant revision has a higher 
success rate (75%) compared to DAIR with exchange (64%) and DAIR with 
non-exchange (48%).8  
The most common types of implant extracting procedures are the one- and two-
stage revision procedures. Both methods imply the extraction and re-
implantation of an implant. However, the timing of re-implantation is what 
differs between the methods. In the one-stage procedure, the infected implant 
is extracted and a new one is implanted during the same procedure (Figure 
13A) . The patient is thereafter subjected to antimicrobial therapy. For the two-
stage procedure, the implant is extracted and then re-implanted once the patient 
is considered infection free (Figure 13B) . During the interim period of the two-
stage procedure, the patient receives antimicrobial treatment. Antimicrobial 
treatment is ceased at least two weeks prior to re-implantation to increase 
chances of representative culture results at stage two.32  
The interim period without a prosthesis can last for several months. During this 
period, the patient is left without a functioning hip joint (a so-called 
Girdlestone situation, Figure 14)  or is given a temporary articulating joint i.e. 
a spacer, most often combined with antibiotic-loaded cement. The interim 
period is associated with a lot of emotional and physical distress for the 
affected patient.1  
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Table 4. The differences in definitions and success rates in recent studies on the 
DAIR procedure. 
Study Success 
rate 
Population Follow-
up 
Time from 
index surgery 
Definition of 
success 
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surgery 
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et al. 201740 
67% 
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DAIR) 
85% 
(multiple 
DAIR) 
122 
(THA) 
M 7 yrs <13 weeks Separate 
definitions for 
single and 
multiple 
DAIR 
Uriarte et al. 
2019141 
27% 26 
(THA) 
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yr= year, AB=antibacterial treatment, THA=total hip arthroplasty, TKA=total knee arthroplasty, M=mean 
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**=Revision THA included in study cohort. 
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Previous surgery such as multiple DAIRs, is associated with a higher failure 
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rate.34 The experience of the surgeon conducting DAIR may also affect results, 
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Figure 13. A schematic illustration of the one-stage method where the infected implant 
is exchanged within the same procedure and the patient thereafter continues with 
systemic antimicrobial treatment (A), and the two-stage method where the patient is 
left without implant after the infected implant has been extracted (B). The patient in 
14B has received a temporary joint (spacer) during the interim period without a 
prosthesis. During this period the patient also receives systemic antimicrobial 
treatment. 
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One- or two-stage treatment? 
“It’s taken a lot of mobility away so that actually takes away entertainment, interests [...] It’s 
just the pure reduction in mobility that is the nuisance. It’s taken away the bowls, it’s taken 
away the walking”. 
Patient,	Roger	in	Moore	et	al.1 
 
Overall, success rates of the one- and two-stage revision procedures lie 
between 70%-94%.143-146 The two-stage method has traditionally been 
considered the gold standard due to better infection resolution. However, 
recent data has not been able to show a difference in infection resolution 
between the two methods.147-149 Furthermore, the one-stage method has 
recently gained more attention due to its assumed patient and cost benefits, 
being just one procedure instead of two. Great distress has been described in 
patients undergoing the two-stage procedure, with one study participant 
reporting thoughts of suicide during the interim period.1 Further, surgeons find 
evidence for decision-making is lacking,150 and there is an ongoing debate on 
how to best utilize the methods. The first randomized study to evaluate them 
is currently being conducted and results are expected in 2020.151 
  
Given the recent findings in favour for the one-stage procedure, UK surgeons 
report on being more open-minded to the one-stage.150 However, the two-stage 
method is still used in the majority of cases. According to current 
recommendations the one-stage can be considered in patients with good tissue 
conditions and in whom the causative agent is known and has good 
susceptibility to antimicrobial agents.123, 152  
Salvage procedures 
 
In some infected patients, salvage procedures may be the most viable option. 
Usually, the patient undergoes Girdlestone resection arthroplasty in which the 
components of the prosthesis are removed (Figure 14). Patients may, or may 
not, undergo a re-implantation of a new implant later on when the infection has 
healed. A permanent Girdlestone hip, arthrodesis of the knee, or in the worst-
case amputation and even exarticulation may occasionally become an 
alternative in desolate cases with long standing infection. These alternatives 
should only be considered when prior surgical treatment has failed. 
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Figure 14. An X-ray image of a Girdlestone hip (to the right in the image). The hip 
prosthesis has been excised leaving the patient without a functioning hip joint.  
 
Algorithms for surgical treatment 
 
The CRIME80-score and KLIC-score are suggested algorithms that may pre-
operatively aid in the choice of surgical treatment as they can be used to predict 
failure rates of DAIR (Figure 15, Figure 16).38, 136, 153 The algorithms consider 
patient related factors and may be of use in early PJI or PJI of haematogenous 
origin when the causative bacterium is unknown.136  
 
The KLIC-score considers kidney disease, liver disease, index surgery (due to 
femoral neck fracture or revision), fixation of implant and the systemic 
inflammation measured using C-reactive protein (CRP) (Figure 15). A KLIC-
score of two or less has been associated with a failure rate of 4.5%38 to 27.9%154 
after DAIR. The KLIC-score may be a good predictor of failure of DAIR,38, 154 
and is suggested to add value for patients with KLIC-score < 3.5 or >6,154 but 
needs to be further evaluated.  
 
The CRIME-80 score considers chronic pulmonary disease (COPD), CRP-
levels, rheumatoid arthritis, index surgery, sex, exchange of modular 
components during DAIR and age (Figure 16). A CRIME80-score ≥ 3 seems 
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to favour the choice of revision surgery, as DAIR has a success rate of 32% 
compared to 83% after revision surgery.8  
The choice of treatment may become more difficult if the first intervention 
fails. Several factors, such as patient comorbidities, type of bacteria, 
complexity and consequences of implant removal and not least the personal 
opinion of the patient have to be considered.  
Figure 15. The KLIC-score model as suggested by and adapted from Tornero et al.38 
Figure 16.  The CRIME-80-score as suggested by and adapted from Wouthuyzen-
Bakker et al.153 
2.3.2 Antimicrobial treatment 
Antimicrobial therapy alone is not sufficient for the treatment of PJI.60 As 
treatment consists of a combination of antimicrobial agents and surgery, it is 
necessary that the antimicrobial therapy is adequately tailored to optimize the 
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chance of successful treatment outcomes. Antimicrobial treatment needs to be 
tailored considering factors such as type of microbe and its antimicrobial 
susceptibility, the patient’s comorbidities, medications, allergies and 
intolerances. 
Type of antimicrobial treatment 
Antimicrobial treatment needs to target both actively dividing and dormant 
bacteria in order to be efficient in BAI. Therapy most often includes rifampicin 
which has a high activity towards biofilm producing bacteria, especially 
staphylococci.155 Rifampicin has a good effect on dormant bacteria and is 
associated with a high bioavailability.32, 155 However, rifampicin is never 
administered as monotherapy due to the development of resistance, therefore 
it  should be reserved for selected patients.155 Rifampicin in polytherapy with 
fluoroquinolones, such as ciprofloxacin, has been reported ideal.155, 156 The 
microorganism’s ability to reside internally in connective tissue and muscle 
cells poses a difficulty, stressing the importance of choosing an antimicrobial 
agent which targets intracellular bacteria.109  
Systemic antimicrobial treatment 
Systemic antimicrobial treatment can be administered either intravenously or 
orally.  Vancomycin or isoxazolylpenicillin e.g. cloxacillin are frequently used 
as empirical postoperative intravenous antimicrobials. Vancomycin has been 
reported to impair biofilm growth when sensitive S. aureus are grown in 
vitro.56 Intravenous antimicrobial treatment administered for less than 
two weeks may contribute to a greater resistance to subsequent rifampicin.157  
Antimicrobial treatment is recommended for a period of two weeks to 
six months.123, 156 There is a dearth of evidence on treatment duration in 
correlation to treatment success. Zimmerli et al. proposed treatment of 
12 weeks regardless of type of surgery.32 However, combined with two-
stage revision surgery, treatment duration can be reduced, in 
Sweden the current recommendation is six to eight weeks.158 There are 
reports on good treatment success (rates of 88-89%) using systemic 
treatment during an even shorter period of time, from using no systemic 
antimicrobials,146 to a regime of one week, in two-stage revision surgery.159  
Local antibiotic treatment 
Intra-operatively, local antimicrobial treatment in the proximity of the hip or 
knee joint can be used. Broad-spectrum antimicrobials such as vancomycin 
and aminoglycosides (gentamycin, tobramycin) are commonly used for local 
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therapy. The use of more than one local antimicrobial agent has proven more 
efficient in microbial eradication.160 The use of antibiotic-impregnated cement 
has increased.4 A recent study showed lower revision rates in primary THA 
due to PJI when antibiotic-impregnated cement was used.118 Alongside 
antimicrobial-impregnated cement, antimicrobial-loaded beads are a further 
alternative.160 The use of local antimicrobials without further intravenous or 
oral treatment has been evaluated in two-stage revision for PJI of TKA, and 
local delivery may be sufficient on its own.146   
Side effects and medical interactions 
“Oh,	they	were	terrible.	It	was	a	hard	time	to	keep	food	down	and	things.	It’s	awful.”	
Patient	Catherine	(Moore	et	al.1)	
Antimicrobial treatment can be associated with side effects in patients such as 
bowel symptoms, urticaria and nausea.5, 6, 155 Side effects may be of such a 
troublesome nature that compliance to medication may become threatened.5 
For rifampicin, if side effects arise, dose reduction or switching to single daily 
dose can be considered.155 
“So when I came home, I stopped taking the medicine because I decided I couldn't sit on the 
loo forever. So I told a few lies.” 
Patient (Andersson et al.5) 
For some patients, treatment options may be limited due to AMR. Furthermore, 
in these patients there may be no viable oral treatment alternative due to 
interactions or side effects in which case an extended period of intravenous 
should be used.123 The patient’s general medication prior to the initiation of 
antimicrobial treatment needs to be considered. Potential medical interactions 
can be difficult to manage if resistance in antibiograms of causative bacteria 
limit the choice of antimicrobial strategies. 
Dosage 
An adequate dose of antimicrobial agents is important for infection eradication. 
Dosage is guided using the MIC susceptibility testing, as previously described. 
However, MIC values are obtained in vitro and the dose and uptake of different 
types of tissue in vivo needs to be considered. Furthermore, MIC guidance of 
treatment may not be suitable in BAI since dormant biofilm bacteria may be 
exposed to sub-inhibitory concentrations.  
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Several factors may affect the antimicrobial concentration reached at the 
infected site. One such factor is the tissue penetrance, where bone, especially 
cortical bone, can present a challenge. Serum concentrations of antimicrobials 
need to be high in order to achieve adequate concentrations in bone tissue. 
Furthermore, the antimicrobial activity is determined by how much of the 
antimicrobial agent is freely circulating and not protein-bound. MIC is based 
on the freely circulating active antimicrobial concentration. The patient’s 
compliance to treatment and the bioavailability are other factors which also 
affect the antimicrobial concentration and are difficult to monitor.  
 
Suppressive antimicrobial treatment 
	
Suppressive antimicrobial therapy is used in patients who are not deemed 
suitable for or who do not wish to undergo further surgery. It is considered a 
viable option if an adequate antimicrobial, tolerated by the patient, can be 
administered. Suppressive treatment, most often lifelong, is generally 
considered in patients where previous surgical treatments have failed, or in 
elderly or frail patients in whom further surgery is contraindicated. One study 
investigated the efficacy of suppressive treatment and reported it successful in 
56.5% of patients.161 In this study, the majority of patients (82.6%) had 
undergone previous revision surgery. In 80% of the failed cases, Girdlestone 
resection arthroplasty was used as final treatment.  
 
Prophylactic antimicrobial use during surgery 
 
During the reversible adherence of bacteria, namely before forming a biofilm, 
bacteria are still susceptible to antimicrobials which supports the use of 
prophylactic antibiotics during arthroplasty surgery.50 Although a small study 
set, THA patients who did not receive intravenous prophylaxis had a 60% 
higher risk for revision due to PJI.18 The risk for revision decreases when 
combining intravenous antimicrobial treatment and local treatment (i.e. cement 
loaded with antimicrobial agents) as prophylaxis.162 However, it is suggested 
that local antimicrobials may elute sub-inhibitory concentrations which may 
enable bacterial adhesion and growth on implants, and promote the 
development of AMR.54  
2.3.3 Antimicrobial resistance  
 
Antimicrobial resistance (AMR) is a microbe’s ability to grow in presence of 
antimicrobial agents.163 An increase in multi-resistant bacteria causing PJI has 
been reported.36 In patients treated with a two-stage procedure and antibiotic-
loaded spacer, an increase in resistance in relapsing S. aureus from stage one 
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to stage two have been observed.164 In this study, patients were treated with 
vancomycin spacers in the interim period and in nine (30%) cases, the strains 
recovered from stage two were more resistant to vancomycin than in the first 
stage. Further, viable bacteria have been found on retrieved spacers from 
patients treated with two-stage revision after antimicrobial treatment has 
cessated.165 This finding adds on to knowledge on the importance of biofilm 
formation for AMR.  
 
In the US, an estimate  of 38.7% to 50.9% of microorganisms causing surgical 
site infection may be resistant to routinely used antimicrobial agents.166 This 
most likely has consequences for procedures requiring prophylactic 
antimicrobials such as prosthetic joint surgery. An improper use of 
antimicrobial agents, such as for growth promotion in the livestock industry, 
has resulted in an increased AMR. Resistance genes can be transferred from 
animals to humans.167, 168 Patients infected by multi-resistant bacteria have a 
greater risk for treatment failure than if infected with susceptible bacteria.169, 
170 In Sweden, methicillin-resistant S. aureus (MRSA) are relatively 
uncommon,171, 172 and screening programs have been established for patients at 
risk for MRSA prior to hospital admission as a measure to reduce its spread 
within the healthcare system.173 
 
AMR is projected to be one of the greatest challenges of our time.174 To address 
AMR, several tentative strategies are discussed and evaluated in research. One 
such in BAI is to target the biofilm at different stages of the biofilm life cycle, 
such as adhesion, cell-to-cell interactions such as quorum sensing, production 
of the EPS matrix and inducing biofilm detachment.47, 49, 109, 175 However, the 
complexity of biofilms impose challenges in developing targeted anti-biofilm 
therapeutics and biofilm-associated infections should perhaps be treated using 
the combination of multi-targeting therapeutics.49 Another preventative 
measures is vaccines, this has not yet had a break-through, although several 
attempts to find a vaccine against S. aureus have been made.176  
 
A general decrease in infection rates have been observed in the U.S. which 
may be a result of the Centres for Disease Control and Prevention’s (CDC) 
work on prevention strategies and AMR awareness.174 As the successors to 
antimicrobial agents yet have to be found, it is important to work with stringent 
infection prevention, focusing on minimizing the known risk factors for PJI. 
As described, research in PJI has greatly increased during the past years and 
there is no reason to believe that this will change in the near future. However, 
it is of importance that researchers collaborate and bring in different 
competences in their teams to ensure a comprehensive multidisciplinary 
approach, combine research methodologies and translate pre-clinical studies 
and protocols to clinical significance. 
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Antimicrobial resistance (AMR) is a microbe’s ability to grow in presence of 
antimicrobial agents.163 An increase in multi-resistant bacteria causing PJI has 
been reported.36 In patients treated with a two-stage procedure and antibiotic-
loaded spacer, an increase in resistance in relapsing S. aureus from stage one 
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to stage two have been observed.164 In this study, patients were treated with 
vancomycin spacers in the interim period and in nine (30%) cases, the strains 
recovered from stage two were more resistant to vancomycin than in the first 
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As described, research in PJI has greatly increased during the past years and 
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and protocols to clinical significance. 
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2.4 THE IMPACT OF PROSTHETIC JOINT 
INFECTIONS 
As briefly mentioned, PJI has a great impact on the affected patient,1 on health 
care resources,9-11 and on the treating surgeon.177 This is important to keep in 
mind when managing PJI and may influence treatment directions. All three 
aspects will be further described in this section. 
2.4.1 Patient impact 
Patients report on psychological and physical suffering when reflecting on 
their experiences of PJI.1, 5, 6 Andersson et al. interviewed patients with implant 
related surgical site infection whereof eight had PJI.5 There were several stages 
during an infection which affected the patient negatively; insecurity about their 
own role in the emergence of infection with feelings of fear and panic at 
symptom onset, uncertainty during diagnostics, in part due to the doctor’s 
uncertainty and due to lack of answers after different examinations, and the 
feeling of not being taken seriously. The latter was further confirmed in a UK-
based study by Moore et al. on the patient experience of PJI.1 
"I knew there was something seriously wrong. I was going to my GP probably once a fortnight 
saying, “I can’t stand this anymore. I don’t seem to be getting any better” [...] I knew that the 
pain was not a muscle pain. I’d been through the procedure once before. It was a most 
distressing time because nobody seemed to be actually hearing what I was saying.” 
Patient Maggie (Moore et al.1) 
Patients felt feelings of worry, suspense, isolation and had experiences of 
depression while waiting for infection resolution. Some had persistent wound 
leakage and returned to the hospital several times.5 Many worried about 
persisting physical disabilities, particularly patients undergoing two-stage 
treatment. In this group, negative social consequences of their physical 
disability were described, and confirmed by Moore et al.1 
"Well	we	used	to	go	out	almost	every	week	[...]	with	our	friends,	we	don’t	seem	to	do	that	
much	now,	my	husband	tends	to	have	to	do	a	lot	for	me	now,	I	mean	silly	things	like	you	
know	my	feet,	my	toenails,	because	when	I	bend	this	is	hurting	me	all	and	everything	like	
that	so..."	
Patient	Wendy	(Moore	et	al.1) 
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Patients witnessed on not being able to return to their normal life after having 
recovered from PJI due to different physical limitations. Others were able to 
manage without further problems. Some felt bitter towards the hospitals and 
doctors, whereas others reflected upon their journey with a new-found 
gratitude towards life. Further, patients could continue feeling fear of recurrent 
infection after treatment.1, 6 
"That’s	my	biggest	fear	because	it’s	a	painful	experience	I	can	tell	you	because	I	did	it	three	
times	and	it’s	the	most	excruciating	painful	experience	you	can	have	[...]	I’m	still	living	in	
fear	of	doing	things	right,	after	the	operation	you	know?"	
Patient	Don	(Moore	et	al.1) 
Andersson et al. described that the patient’s social relationships were the key 
source of support during treatment and sometimes the patient’s situation put a 
strain on their relationships.5 Some patients also described their relationship 
with their doctor as an important source of strength and support.5 
Linnéa Teljas Puranen 
Figure 17.  A patient and surgeon meeting. 
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2.4.2 Surgeon impact 
Given the mentioned uncertainties within several aspects of PJI, the 
management of PJI consists of many challenges. Prosthetic joint surgeons feel 
uncertain when deciding on treatment plans for PJI as there is lacking evidence 
to support the superiority of available methods.150 As mentioned, low virulent 
infections can be hard to diagnose as patients can present with unspecific 
symptoms. It can be difficult to secure reliable cultures that represent the 
causative microbe, and it is hard to interpret which bacterial growth is 
significant and which is sample contamination.  
Meeting patients who are in a distressed state and seeing how they, in some 
cases, physically and mentally deteriorate may be a difficulty. Physicians may 
be exposed to a risk of developing anxiety, burnout and/or depression in 
encounters with traumatic events or adverse events. Physicians with ill-being 
and workplace related stress may be unable to give optimal care to their 
patients due to higher frequencies of adverse events and reduced 
productivity.178 The term second victim was first used in 2000 to describe how 
adverse events can have a negative impact on the treating physician.179 
After an adverse event, a physician may experience feelings of guilt, 
frustration, anger, fear and distress.180-182 Study participants have reported high 
emotional impact when missing a diagnosis, doubting a medical decision, 
during life-threatening moments and bad news conversations, when severe 
complications arise, and when meeting unsatisfied patients.183  
Within orthopaedics, Mallon et al. investigated the impact of PJI on prosthetic 
joint surgeons in the UK.177 They reported that PJI had a deep negative impact 
on the surgeon and that surgeons felt accountable for the infection.  
Several studies have shown that physicians would like the possibility of peer 
support after an adverse event.183-185 Many physicians are of the opinion that 
the support systems are insufficient and desire structured support.180, 186, 
187  However, some do not seek help or speak up  due to stigma.187 Little is 
known about what support strategies prosthetic joint surgeons may need.  
2.4.3 Economic impact 
PJI is associated with a significant economic burden and the economic impact 
has been investigated in several different countries.9-12, 188, 189 Considering the 
projections on an increase in the numbers of primary arthroplasty 
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procedures,20, 24, 25, 190 PJI-related costs will increase. Furthermore, the increase 
of AMR, such as methicillin-resistance, has also been linked to greater costs.13 
 
A Finnish study reported on the following mean cost per patient for THA and 
TKA procedures: primary procedure (€7,200), DAIR treatment (€18,461) and 
two-stage treatment (€38,428 for stage one and €17,240 for stage two).10 
Another study reported on a near five-fold increase in costs for revision due to 
PJI compared to the primary procedure.9 
 
PJI patients were hospitalized for a longer time period, up to an average of 
seven times longer compared to primary procedures,9, 10, 188, 189 which implies a 
greater cost. Also, in presence of methicillin-resistant bacteria, length of stay 
significantly increased.13 PJI patients also required more out-patient visits.9, 10, 
189 Furthermore, the impact of indirect hospital costs should be considered. In 
the US, the total costs of PJI calculated in a model of direct hospital and 
indirect societal costs for one patient ranged from USD 390,806 up to USD 
474,004.11 This model also considered loss of productivity.   
 
In light of the economic perspective, it is important to identify time-efficient 
and less expensive methods for diagnosis and treatment of PJI. 
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2.5 CURRENT GAPS IN KNOWLEDGE THAT 
MOTIVATE THIS THESIS 
 
The gaps of knowledge mentioned in this section are those that motivate the 
projects included in this thesis.  
 
• There is a need for improved diagnostic tools to aid tailored 
treatment of PJI. It is important to determine the bacterial 
virulence factors involved in the pathogenesis of PJI and at an 
early stage. Biofilm production and susceptibility may be 
associated with clinical outcome in PJI and MBEC may be a 
surrogate marker for biofilm producing bacteria, but this has 
yet to be evaluated. (Paper I) 
 
• The success rates of DAIR vary in the current literature. The 
success rate of DAIR in PJI of the hip has not been 
investigated using the Swedish Hip Arthroplasty Register. 
The role of DAIR in treatment algorithms in regard of the 
exchange or non-exchange of modular components has not 
been established for this population. (Paper II) 
 
• Globally, there is an uncertainty in which method (one- or 
two-stage revision) is superior to the other, thus presenting a 
difficulty in treatment choice. The SHAR has collected 
information on one- and two-stage revision procedures due to 
infection since its start in 1979, allowing for a uniquely long 
follow-up time. The success rate of the two methods has not 
previously been studied in the SHAR. (Paper III) 
 
• A solitary study outside Sweden has found a deep impact of 
PJI on the treating surgeon. However, little is known about 
how PJI surgeons cope with the difficulties they may face 
during management of PJI. Furthermore, no study has been 
conducted to describe the emotional impact and experiences 
of PJI on Swedish surgeons or identified improvements in PJI 
management desired by surgeons. (Paper IV) 
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3 AIMS 
 
The specific aims of each study in this thesis were the following. 
 
• To identify whether biofilm production in staphylococci 
causing PJI correlates to clinical outcome, defined as 
infection resolution or recurrence, and to evaluate whether 
biofilm susceptibility testing measured as MBEC has a 
correlation to clinical outcome. (Paper I) 
 
• To establish the success rate of DAIR for PJI with or without 
the exchange of modular components. (Paper II) 
 
• To establish the rates of re-revision after one- and two-stage 
surgery for PJI. (Paper III) 
 
• To investigate the experiences and emotional impact of PJI 
on prosthetic joint surgeons and identify facilitating factors in 
the management of PJI. (Paper IV) 
 
   2 INTRODUCTION 
 40 
2.5 CURRENT GAPS IN KNOWLEDGE THAT 
MOTIVATE THIS THESIS 
 
The gaps of knowledge mentioned in this section are those that motivate the 
projects included in this thesis.  
 
• There is a need for improved diagnostic tools to aid tailored 
treatment of PJI. It is important to determine the bacterial 
virulence factors involved in the pathogenesis of PJI and at an 
early stage. Biofilm production and susceptibility may be 
associated with clinical outcome in PJI and MBEC may be a 
surrogate marker for biofilm producing bacteria, but this has 
yet to be evaluated. (Paper I) 
 
• The success rates of DAIR vary in the current literature. The 
success rate of DAIR in PJI of the hip has not been 
investigated using the Swedish Hip Arthroplasty Register. 
The role of DAIR in treatment algorithms in regard of the 
exchange or non-exchange of modular components has not 
been established for this population. (Paper II) 
 
• Globally, there is an uncertainty in which method (one- or 
two-stage revision) is superior to the other, thus presenting a 
difficulty in treatment choice. The SHAR has collected 
information on one- and two-stage revision procedures due to 
infection since its start in 1979, allowing for a uniquely long 
follow-up time. The success rate of the two methods has not 
previously been studied in the SHAR. (Paper III) 
 
• A solitary study outside Sweden has found a deep impact of 
PJI on the treating surgeon. However, little is known about 
how PJI surgeons cope with the difficulties they may face 
during management of PJI. Furthermore, no study has been 
conducted to describe the emotional impact and experiences 
of PJI on Swedish surgeons or identified improvements in PJI 
management desired by surgeons. (Paper IV) 
 
   3 AIMS 
41 
3 AIMS 
 
The specific aims of each study in this thesis were the following. 
 
• To identify whether biofilm production in staphylococci 
causing PJI correlates to clinical outcome, defined as 
infection resolution or recurrence, and to evaluate whether 
biofilm susceptibility testing measured as MBEC has a 
correlation to clinical outcome. (Paper I) 
 
• To establish the success rate of DAIR for PJI with or without 
the exchange of modular components. (Paper II) 
 
• To establish the rates of re-revision after one- and two-stage 
surgery for PJI. (Paper III) 
 
• To investigate the experiences and emotional impact of PJI 
on prosthetic joint surgeons and identify facilitating factors in 
the management of PJI. (Paper IV) 
 
 4 METHODS AND MATERIALS 
42 
4 METHODS AND MATERIALS 
 
Ethical approvals 
 
All studies received approval from the Regional Ethical Board in Gothenburg, 
Sweden, prior to study start.  
 
Paper I Written consent was obtained from study participants prior to the 
study start. Participants were allowed to withdraw from the study at any point 
without further explanation. Ethical application approved 2016-11-10, entry 
number 654-16.  
 
Paper II Patient consent was not needed for this study according to the Patient 
Data Act in Sweden. Ethical application approved 2017-10-23, entry number 
804-17. Amended to include sending out supplementary data sheets to all 
orthopaedic units in Sweden, approved 2018-01-17, entry number T053-18. 
Amended to include medical record retrieval from orthopaedic units in 
Sweden, approved 2019-03-15, entry number 2019-00957. 
 
Paper III Patient consent was not needed for this study according to the Patient 
Data Act in Sweden. Ethical application approved 2015-07-07, entry number 
430-15.  
 
Paper IV Written and oral consent was obtained from study participants prior 
to the interviews. Participants were allowed to withdraw from the study at any 
point without further explanation. Ethical application approved 2017-02-20, 
entry number 1190-16. Anonymity of the study participants was ensured by 
coding each interview, and only KS had access to the code key. Furthermore, 
geographical location has not been disclosed as a measure to prevent 
identification of study participants. 
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4.1 PAPER I 
 
Study population 
 
The medical records of patients operated due to PJI between 1st January 2012 
to 30th June 2015 were reviewed until 31st December 2018 to collect variables 
of infection interest (Paper I, Table 1). Follow-up was at least 3.5 years for all 
patients (mean follow-up time of 5 years). 
 
Intraoperative tissue samples sent to the Clinical Bacteriological Laboratory 
(Sahlgrenska University Hospital) for culture growth were isolated and stored 
according to routine. For this study, isolated bacterial strains were cultured and 
matched to their respective reoperation and patient, and anonymously coded at 
the Clinical Bacteriological Laboratory. The strains were frozen and 
transported to the Department of Biomaterials (University of Gothenburg) 
where they were further analysed. 
 
Strains were compared with medical records to determine growth in at least 
two out of five or more samples to certify the saved strain’s causative 
significance. Patients were included if they met the following criteria: 
 
• First-time PJI of the hip or knee according to the MSIS 
criteria.124 
• Infection caused by monomicrobial growth of S. aureus or 
CoNS. 
• Infection caused by polymicrobial growth of two different 
staphylococcal species. 
 
Patients without saved strains, who did not consent to analysis of their strains, 
had negative growth, or bacterial growth other than staphylococci, were 
excluded from the study (Paper I, Figure 1). Furthermore, patients with an 
additional diagnosis (e.g. cancer) or bilateral prostheses were also excluded. 
 
Outcome measures 
 
The primary outcome was to identify whether biofilm production (non/weak 
or strong) correlates to clinical outcome (infection resolution or recurrence). 
The secondary outcome was to evaluate the correlation between biofilm 
susceptibility (MBEC, MBEC/MIC-ratios and antibiogram patterns) and 
clinical outcome. 
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Bacterial inoculum preparation and identification of the bacterial strains 
 
The bacterial strains were transported under frozen conditions and immediately 
stored in -80°C upon arrival to the Department of Biomaterials. Prior to 
analysis strains were cultured on 5% horse blood Columbia agar plates at 37°C 
overnight (o.n.). The APIÒ Staph test kit (bioMérieux, Marcy-l’Etoile, France) 
was used to identify CoNS to the specific species level. 
 
Biofilm formation ability of the strains and biofilm quantification 
 
There are several methods to quantify microbial biofilm.191 In the present 
study, the microtiter plate test using crystal violet (CV) was used for biofilm 
quantification. CV is a dye that stains both live and dead cells as well as the 
EPS, allowing for quantification of the total biofilm biomass. One colony from 
each strain was further inoculated overnight (o.n.) in tryptic soy broth (TSB, 
Scharlau, Barcelona, Spain) with an addition of 0.25% glucose for S. aureus 
and incubated at 37°C on a shaker o.n. The optical density (OD) of CV is 
determined by using a microtiter-plate reader. The cell suspension was 
adjusted to OD546=1 and diluted 1:40 in TSB (with an addition of 0.25% 
glucose for S. aureus). Equal amounts of the bacterial suspension (200 µL) was 
added to three wells in a 96-well microtiter plate (BioLite Cell Culture Treated 
Plates, Thermo ScientificÔ, MA, USA). The plates were incubated statically 
for 24h at 37°C and thereafter washed three times in water. The biofilms still 
adherent to the wells were stained with 200 µL of 2% CV (VWR, PA, USA) 
for five minutes and gently washed in water. The wells were thereafter air dried 
and the biofilm bound dye was eluted in 200 µL ethanol-acetone.  A volume 
of 150 µL of the eluted suspension was moved to a new plate and OD595 was 
determined using a plate reader (FLUOstar Omega, BMG Labtech, Offenburg, 
Germany). Three wells served as blanks and contained sterile TSB of which 
the mean value was subtracted from all readings. OD values were averaged in 
accordance to recommendation.192  
 
Biofilm classification 
 
Biofilm production was categorized according to the classification suggest by 
Baldassarri et al.193 For statistical analysis, this classification was further 
modified (Figure 18). Control strains were used as references for the different 
biofilm production categories (Table 5). 
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Figure 18. The Baldassarri classification193 for biofilm production and the modified 
version used for the analyses of the current study.  
Table 5. Reference strains for biofilm production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biofilm susceptibility testing: MBEC and MIC 
 
A Calgary Biofilm Device (CBD, MBEC AssayÒ, Innovotech Inc., Edmonton, 
Canada), a microtiter plate consisting of 96 wells, was used to grow biofilm 
(Figure 19).194, 195 The CBD was combined with an antimicrobial plate of eight 
commonly used antimicrobial agents in PJI treatment (CML2FNUN: 
SensititreÔ, MA, USA).  The SensititreÔ was produced with increasing 
antimicrobial concentrations based on levels for MIC determination and values 
above clinical breakpoints (0.25 to 1216 µg/mL) (Paper I, Figure 3).  
 
MBEC was determined according to Zaborowska et al. and schematically 
illustrated in Figure 2 of Paper I.58 A volume of 150 µL of a bacterial inoculum 
(107 CFU/mL) of each strain in Mueller-Hinton Broth 2 was added in the 96 
wells of the CBD and then incubated for 24 h at 37°C on a shaker (125 rpm) 
for biofilm formation on the CBD-pegs (Figure 19). 
Biofilm production category Reference strain  
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Non-producer ATCC 12228 (ica negative)  
Strong producer ATCC 35984 
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Non-producer 15981 (ica negative) 
Strong producer 15981 
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Bacterial inoculum preparation and identification of the bacterial strains 
 
The bacterial strains were transported under frozen conditions and immediately 
stored in -80°C upon arrival to the Department of Biomaterials. Prior to 
analysis strains were cultured on 5% horse blood Columbia agar plates at 37°C 
overnight (o.n.). The APIÒ Staph test kit (bioMérieux, Marcy-l’Etoile, France) 
was used to identify CoNS to the specific species level. 
 
Biofilm formation ability of the strains and biofilm quantification 
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Scharlau, Barcelona, Spain) with an addition of 0.25% glucose for S. aureus 
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determined by using a microtiter-plate reader. The cell suspension was 
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accordance to recommendation.192  
 
Biofilm classification 
 
Biofilm production was categorized according to the classification suggest by 
Baldassarri et al.193 For statistical analysis, this classification was further 
modified (Figure 18). Control strains were used as references for the different 
biofilm production categories (Table 5). 
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Figure 19. The Calgary Biofilm Device (to the left) consists of a lid with 96 pegs and 
a base with corresponding wells that enables the testing of antimicrobial agents 
against biofilms. A single peg and well is illustrated to schematically show the 
adhesion of bacteria from the wells to the peg lids and the formation of biofilm (seen 
in yellow) on the peg lids.   
 
Quantification of viable bacteria on the peg (CFU/peg) was performed by 
removing four pegs with sterile equipment and thereafter washed, vortexed for 
1 minute and sonicated for 1 minute (at 40 Hz) to dislodge the biofilm in saline. 
The dislodged cells were diluted and cultured o.n. on blood agar plates. 
 
For MBEC determination, the peg lids were rinsed with saline and placed in 
the custom-made SensititreÔ for approximately 20h at 37°C. The peg lids 
were thereafter rinsed two times, placed in a neutralizing agent and finally 
sonicated for 1 minute to dislodge the biofilm into the recovery plate wells. 
After o.n. incubation at 37°C, MBEC was determined visually using the 
SensititreÔ Manual Viewbox (Figure 20). 
 
MIC was determined using planktonic cultures for all strains, as described by 
Zaborowska et al.58 A volume of 100 µL containing an equivalent 
concentration to the CFU/peg for the same strain was added to the wells of the 
SensititreÔ plate. The plates were incubated for approximately 20h at 37°C. 
The Manual Viewbox was used to determine the MIC. 
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Figure 20. An example of the process of determining the MBECs for each strain and 
all tested antimicrobial agents. The figure shows the antimicrobials and 
concentrations of the custom-made SensititreÔ plate.  Each colour represents a 
different antimicrobial agent and the numbers reflect the increasing concentrations of 
each antimicrobial agent. There are four empty wells (left column) and two controls 
(right column). Once the biofilms have been dislodged in the recovery plate (which 
does not contain antimicrobial agents) biofilm growth can be determined. The 
illustration shows the principles of this process where the purple bacteria in the figure 
represent growth. Using the known concentrations for each well the eradication 
concentration can be determined (the first concentration at which there is no growth). 
In the example above, the bacterial strain needs 64 µg/mL of the first antimicrobial 
(light blue colour) to eradicate biofilm growth. 
 
Study definitions 
 
Infection resolution was defined as no further suspicion of infection based on 
clinical judgement, laboratory tests and no further treatment (both 
antimicrobial and surgical) due to PJI.   
 
Recurrent infection was defined as either a reinfection with an unrelated 
bacterial strain, or infection relapse i.e. the growth of an identical strain.  
 
Symptom onset was defined as the first time a patient contacted the health care 
system with a suspicion of infection.  
 
Duration of antimicrobial treatment was defined as the time period between 
post-operative commencement until cessation of planned therapy, or the date 
of any further surgery due to PJI. 
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Study definitions 
 
Infection resolution was defined as no further suspicion of infection based on 
clinical judgement, laboratory tests and no further treatment (both 
antimicrobial and surgical) due to PJI.   
 
Recurrent infection was defined as either a reinfection with an unrelated 
bacterial strain, or infection relapse i.e. the growth of an identical strain.  
 
Symptom onset was defined as the first time a patient contacted the health care 
system with a suspicion of infection.  
 
Duration of antimicrobial treatment was defined as the time period between 
post-operative commencement until cessation of planned therapy, or the date 
of any further surgery due to PJI. 
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Surgical treatment was defined as either implant preserving (DAIR, exchange 
or non-exchange) or implant extracting (any type of revision surgery involving 
the cup and/or stem). 
 
Antimicrobial susceptibility was determined using the EUCAST definitions 
and breakpoints for staphylococci (Appendix, Supplementary Table 1).133 
Susceptibility was tested using the MICs and the MBECs for all antimicrobial 
agents for each strain. 
 
The absolute MBEC values were further dichotomized to high values 
(MBEChigh) or low values (MBEClow) for the most potent anti-biofilm active 
antimicrobial given (Figure 21). Rifampicin was considered the most potent 
antimicrobial in cases where the patient had received polytherapy. 
 
Each bacterial strain was analysed in terms of biofilm production, MICs and 
MBECs. If several strains caused the same infection each strain was 
considered as an entity of infection source and were therefore assigned the 
same clinical outcome. 
 
 
 
 
 
 
Linnéa Teljas Puranen/Karin Svensson 
 
Figure 21. How MBEC degree was assigned to each individual strain based on the 
most potent antimicrobial agent the patient received.     
 
Statistical analysis 
 
Descriptive statistics were presented using percentages, means with standard 
deviations (SD) or standard error of the mean (SEM), medians with the 
interquartile range (IQR) or mode and range. 
 
Chi-square test was used to analyze the relationship between i) biofilm 
production (non/weak or strong) and clinical outcome, ii) surgical procedure 
(implant preservation or extraction) and clinical outcome, iii) MBEC 
(MBEClow and MBEChigh) and clinical outcome. Chi-square was also used to 
compare susceptibility when measured using MBEC. Chi-square is a statistical 
test used to test for association between two categorical variables i.e. 
qualitative variables, whereof one is independent and the other dependent. For 
this study, the number of observations exceeded the minimum required (n=20).  
Absolute 
MBEC for most 
potent 
antimicrobial 
EUCAST clinical 
breakpoint for most 
potent antimicrobial 
S = MBEClow 
R = MBEChigh 
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One-Sample T-test was used for the evaluation of absolute values (CV OD) of 
biofilm production intra-species. The One-Sample T-Test was used to compare 
the means of populations.  
 
Mann-Whitney U test was used for the analyses of i) MBEC/MIC-ratios and 
clinical outcome, and ii) comparisons of MBECs and MICs for each 
antimicrobial agent, as these were not normally distributed according to 
Shapiro-Wilk test. Mann-Whitney U test is used to compare two variables, 
often non-parametric. 
 
Binomial univariable logistic regression analysis was performed for biofilm 
production (independent variable) and clinical outcome (dependent variable). 
Logistic regression indicates the probability that an alternative within a 
categorical or continuous variable leads to a certain outcome in a dichotomized 
dependent variable. Odds ratio (OR) are presented with 95% confidence 
interval (C.I.). 
 
Independent Samples T-Test was used for biofilm production (independent 
variable) and MBEC/MIC-ratios (dependent variable). This test compares the 
means between groups in the independent categorical variable on the 
dependent continuous variable, i.e. did the mean MBEC/MIC-ratios for strong 
biofilm producers differ from the mean MBEC/MIC-ratios of non/weak 
biofilm producers 
 
One-way ANOVA was used for the analysis of biofilm production (categorical 
variable) and MBEC/MIC-ratios (continuous variable) for each antimicrobial 
agent. Levene’s test was used to test for homogeneity in variances i.e. that 
variances within each group are equal. 
 
Two-way ANOVA was used to test for interactions between biofilm 
production (independent variable) and clinical outcome (independent variable) 
on MBEC/MIC-ratios (dependent variable) for each antimicrobial agent. In 
other words, the two-way ANOVA analyses the effect of biofilm production 
on MBEC/MIC-ratios influenced by the clinical outcome, and vice versa.  
 
IBM SPSS Statistics (version 26, IBM corporation, USA) and software R 
(version 3.6.1, The R project, Vienna, Austria) were used for the statistical 
analyses. Statistical significance was defined as p-value of less than 0.05. 
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4.2 PAPER II 
 
The Swedish Hip Arthroplasty Register 
 
The Swedish Hip Arthroplasty Register (SHAR) is a nationwide register on 
primary and revision hip arthroplasty which was started in 1979. Initially it 
was meant as a study trial to monitor complications after arthroplasty during 
1976-1977.196 Following the study’s success, the trial transcended to a 
continuous prospective multi-centre study i.e. a register in which all Swedish 
orthopaedic units eventually participated. Individual patient data and several 
parameters associated with implant survival were collected and added on 
throughout the years. Data such as sex, age, ASA-class, BMI, surgical side, 
operation unit and implant specific details are collected. The SHAR has a 
100% coverage and for 2018 data completeness was 98% for primary THA 
and 92% for revision THA.2 Each unit has an assigned contact doctor and 
contact secretary. Baseline data is inputted by specially trained secretaries at 
each hospital. Mortality data on patients is obtained using the Swedish Tax 
Agency which is linked to the SHAR. 
 
The SHAR reports openly on its data and publishes an annual report available 
for anyone to access on their website (www.shpr.registercentrum.se). Quality 
measures include reoperations within two years after surgery, re-admission 
within 30 days after surgery and mortality within 90 days after surgery. 
 
In the SHAR, reoperations are defined as any surgical 
procedure subsequent and in close relation to the primary 
THA. Revision procedures are defined as an exchange or 
extraction of any parts of, or of the entire, prosthesis. The 
reason for a reoperation is reported to the reoperation 
database. Medical records of each reoperation are sent to the 
SHAR for central register inputting to affirm that the 
reoperation codes are correct. 
 
Study population and data retrieval 
 
The SHAR was used to identify all reoperations due to PJI between 1st January 
2009 and 31st December 2016. In order to supplement with data on PJI, report 
forms were sent out to the SHAR contact doctors at all orthopaedic units in 
June 2018 (for report form see Appendix, Supplementary Figure 1). Data was 
retrieved from the participating centres between September 2018 and 
November 2019. If a centre was interested in participating but was unable to 
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conduct the journal reviews, KS was granted access to journals first-hand. One 
centre sent copies of the concerned medical journals for KS to review. 
 
The database containing the supplementary data was merged to the SHAR 
reoperation database to add on data on previous and subsequent surgery. 
 
Patients were eligible for the current study if they fulfilled the following 
criteria (study inclusion is illustrated in Paper II, Figure 1): 
 
• A registered DAIR operation for a first-time diagnosis of PJI 
after primary THA where PJI was defined according to the 
major criteria of the MSIS definition with further 
modification to include patients with intraoperative 
purulence.  
 
Patients were excluded due to the following: 
 
• Treatment with delayed wound closure after DAIR 
(secondary suturing). 
• Concurrent sepsis.  
• Bilateral PJI. 
• Known endocarditis or known terminal cancer. 
 
Outcome measures 
 
The primary aim of this study was to compare the success rate of DAIR when 
modular components (femoral head and/or liner) were exchanged (exchange) 
compared to when they were let be (non-exchange). The primary outcome was 
defined as any further reoperation due to infection within two years after the 
first DAIR procedure. The DAIR procedure was considered successful if no 
subsequent reoperations due to PJI within two years were conducted. 
 
The secondary aim of this study was to compare non-exchange and exchange 
DAIR in terms of subsequent revision procedures (revision of any bone-
anchored implant component i.e. the femoral stem and/or the acetabular cup) 
due to PJI within two years. 
 
Study definitions 
 
Symptom onset was defined as the first time the patient contacted the health 
care system with a suspicion of PJI. Symptom onset was defined as the date of 
surgery in cases where patients presented with symptoms immediately after 
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Symptom onset was defined as the first time the patient contacted the health 
care system with a suspicion of PJI. Symptom onset was defined as the date of 
surgery in cases where patients presented with symptoms immediately after 
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their operation (typically wound leakage). Symptom onset was set to the first 
day of the month if the day of symptom onset was unknown but the month and 
year were reported. 
 
Polymicrobial infections were defined as the presence of more than one 
bacterial species in the culture results. The sub-species level was not 
determined for all CoNS and they were therefore regarded in their entity. 
Staphylococcus aureus and Staphylococcus lugdunensis were grouped 
together due to their similar virulence.197 
 
Duration of antimicrobial treatment was pre-defined in time intervals (< 4 
weeks, 4-8 weeks, 8-12 weeks and > 12 weeks) in the questionnaires. The end 
date of treatment was either the date of treatment failure (i.e. the date for a new 
reoperation) or the date of treatment cessation. Oral antimicrobials were 
registered at the date of discharge and any change in antimicrobial therapy was 
noted. Patients with further reoperations within the same hospitalisation period 
were registered without oral therapy as this had not been commenced 
subsequent their first DAIR.  
 
Statistical analyses 
 
Kaplan-Meier survival analysis was used to compare the exchange of modular 
components to non-exchange in terms of survivorship (defined as no further 
reoperation) two years subsequent the initial DAIR procedure. Patients were 
censored at death or new reoperation. Kaplan-Meier survival analysis was also 
used with revision of bone anchored components as endpoint. Kaplan-Meier is 
a nonparametric method for the estimation of probable survival for a set time 
point and plots the survival distribution. 
 
The risk for a new reoperation was calculated using Cox regression analysis 
comparing exchange and non-exchange DAIR. The following variables were 
considered potential confounders: age, sex, BMI, method of fixation, bacterial 
growth and symptom duration from primary procedure and duration from 
symptom onset to DAIR. ASA-class was not available for the entire cohort, 
and a sensitivity analysis including aforementioned variables and ASA-class 
was performed on the cohort in which it was available. Proportional hazard 
assumption was checked by visually inspecting the Schoenfeld plots. 
Antimicrobial treatment was not included in the regression analysis due to 
difficulties in grouping this data. Hazard ratios (HR) are presented with 95% 
confidence interval (C.I). Cox regression analysis is a type of multivariable 
regression analysis. Regression analysis can be used for the prediction of the 
outcome of the dependent variable (exchange/non-exchange DAIR) based on 
the independent variables (potential confounders). 
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In a sub-group, data on suppressive antimicrobial therapy and persisting 
clinical symptoms of infection was available. This group was presented using 
descriptive data in attempt to obtain the rate of true infection resolution. 
Infection resolution was defined as no further reoperation, suppressive 
antimicrobials or clinical signs of infection. 
 
Data analysis was performed using software R (version 3.6.1, The R project, 
Vienna, Austria).  
4.3 PAPER III 
 
The SHAR 
 
This study analysed prospectively collected longitudinal cohort data from the 
SHAR. For a description of how data collection is conducted within the SHAR 
please see the mthods description for Paper II (page 50). 
 
Study population 
 
Patients who had received a THA due to osteoarthritis and undergone a one- 
or two-stage revision procedure due to infection between 1979-2015 were 
eligible for analysis. Each THA was studied separately in cases of bilateral PJI.  
 
Outcome measures 
 
Re-revision regardless of cause was the primary endpoint. Analysis of re-
revision due to aseptic loosening and infection was performed as secondary 
endpoints. 
 
Study definitions 
 
In the SHAR revision procedures are defined as the exchange of parts of or the 
entire prosthesis alternately, definite extraction of the prosthesis. In this study 
one-stage revision was defined as exchange of the entire prosthesis and each 
THR was studied separately in cases when patients had bilateral PJI. 
 
Infection was defined using the code for revision as entered in the SHAR. 
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their operation (typically wound leakage). Symptom onset was set to the first 
day of the month if the day of symptom onset was unknown but the month and 
year were reported. 
 
Polymicrobial infections were defined as the presence of more than one 
bacterial species in the culture results. The sub-species level was not 
determined for all CoNS and they were therefore regarded in their entity. 
Staphylococcus aureus and Staphylococcus lugdunensis were grouped 
together due to their similar virulence.197 
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weeks, 4-8 weeks, 8-12 weeks and > 12 weeks) in the questionnaires. The end 
date of treatment was either the date of treatment failure (i.e. the date for a new 
reoperation) or the date of treatment cessation. Oral antimicrobials were 
registered at the date of discharge and any change in antimicrobial therapy was 
noted. Patients with further reoperations within the same hospitalisation period 
were registered without oral therapy as this had not been commenced 
subsequent their first DAIR.  
 
Statistical analyses 
 
Kaplan-Meier survival analysis was used to compare the exchange of modular 
components to non-exchange in terms of survivorship (defined as no further 
reoperation) two years subsequent the initial DAIR procedure. Patients were 
censored at death or new reoperation. Kaplan-Meier survival analysis was also 
used with revision of bone anchored components as endpoint. Kaplan-Meier is 
a nonparametric method for the estimation of probable survival for a set time 
point and plots the survival distribution. 
 
The risk for a new reoperation was calculated using Cox regression analysis 
comparing exchange and non-exchange DAIR. The following variables were 
considered potential confounders: age, sex, BMI, method of fixation, bacterial 
growth and symptom duration from primary procedure and duration from 
symptom onset to DAIR. ASA-class was not available for the entire cohort, 
and a sensitivity analysis including aforementioned variables and ASA-class 
was performed on the cohort in which it was available. Proportional hazard 
assumption was checked by visually inspecting the Schoenfeld plots. 
Antimicrobial treatment was not included in the regression analysis due to 
difficulties in grouping this data. Hazard ratios (HR) are presented with 95% 
confidence interval (C.I). Cox regression analysis is a type of multivariable 
regression analysis. Regression analysis can be used for the prediction of the 
outcome of the dependent variable (exchange/non-exchange DAIR) based on 
the independent variables (potential confounders). 
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Statistical analysis 
 
Demographic data was analysed descriptively using the mean and standard 
deviation (SD).  
 
Kaplan-Meier survival analysis and Log rank test was used to compare the 
survivorship between one- and two-stage revision surgery in terms of re-
revision. This was done for revision regardless of cause and for aseptic 
loosening and infection specifically. Truncation was done after 15 years, at this 
point the number of patients at risk was below 100. 
 
Cox regression analysis was conducted and adjusted for sex, age, diagnosis 
(primary and secondary osteoarthritis) and method of fixation (cemented or 
non-cemented). ASA-class and BMI was first registered in the SHAR in 2008. 
Therefore, this data was not available for the entire study population. A 
sensitivity analysis was performed using Cox regression adjusted for sex, age, 
diagnosis, method of fixation, BMI, ASA-class and year of surgery. Hazard 
ratios (HR) are presented with 95% confidence interval (C.I). 
 
IBM SPSS Statistics (version 22, IBM corporation, USA) was used. Statistical 
significance was defined as p-value of less than 0.05. 
4.4 PAPER IV  
 
Study population 
 
In this study, purposive sampling was employed to capture different 
perspectives of the study aim.198 The variables identified as potential 
contributors to diversity in experience that we used to recruit our study 
population were: gender, age, level of workplace (county, district or regional 
hospital), years of experience in arthroplasty surgery and years of experience 
within PJI. Surgeons with any experience of arthroplasty surgery of the hip or 
knee were invited to participate. The study had no exclusion criteria.  
 
Eleven heads of department at orthopaedic units in Sweden were approached 
by e-mail starting October 2017. The units were selected to ensure a variety of 
surgeon volume. Eighteen prosthetic joint surgeons from nine units 
participated in the study. Study recruitment ceased once we considered to have 
reached data saturation i.e. the replication or recurrence of data.199  
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The data source for this study was individual interviews. All 18 interviews 
were conducted face-to-face by the same person (KS) during the period 
December 2017 to February 2018 at the location of the interviewee’s choice. 
The interviews were conducted in a semi-structured manner using a topic guide 
list (Appendix, Supplementary Figure 2). Written and oral consent was 
obtained prior to each interview. Interviews were audio-recorded and were 
transcribed verbatim by a third part.  
 
Outcome measures 
 
The main outcome of this study was to investigate the experiences and 
emotional impact of PJI on prosthetic joint surgeons, and identify desired 
improvements in the management of PJI.  
 
Data analysis 
 
In this study, qualitative content analysis (QCA) according to Graneheim et al. 
was used.200 Data was processed by listening to, and reading, each interview 
repeatedly in order to further familiarise with data. Meaning units were 
identified and extracted from the text in accordance with the study questions. 
The meaning units were condensed and labelled with a code for further 
grouping into categories. Themes evolved from the over-arching implication 
of similar categories. The evolving categories and themes were continuously 
discussed and contrasted within the research group. The analysis process is 
schematically illustrated in Figure 22, and exemplified in Paper IV (Figure 1 
and Table 2). Quotes were professionally translated by a third part to ensure 
objectivity. 
 
Figure 22. A schematic overview of the analytical process according to QCA taking 
the increasing level of abstraction into account for each step. Figure inspired by 
Erlingsson et al.201 
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5 RESULTS 
5.1 PAPER I  
 
Study population and demography 
 
The study population consisted of 49 patients and 70 bacterial strains (Paper I, 
Figure 1). The majority of patients were male (67.3%), had a THA (65.3%), 
had a mild systemic disease (67.3%) and were infected with a monomicrobial 
infection (69.4%) (Paper I, Table 1). Patients with recurrent infections had a 
longer duration to symptom onset from index surgery, however, this was not 
statistically significant. There was a more frequent use of RIF in polytherapy 
in the patients with resolved infections (n=20) compared to recurrent infections 
(n=14). Surgical treatment did not associate with clinical outcome (p=0.8). 
Pre-operative inflammatory markers were similar for patients with resolved 
and recurrent infections (Paper I, Supplementary material, Table S2).  
 
Biofilm production of the bacterial strains 
 
The majority (n=51, 72.9%) of the bacterial strains were categorised as strong 
biofilm producers. A greater proportion of strong biofilm producers compared 
to non/weak producers was observed for all species (S. aureus, S. epidermidis, 
and other CoNS) (Paper I, Figure 4A). Further, the number of viable CFU on 
the pegs of the CBD was similar despite biofilm category (Paper I, 
Supplementary Table S1). 
 
Biofilm production in relation to clinical outcome 
 
Of the 49 patients, 24 (49%) had recurrent infection (Paper I, Table 1). In the 
group of patients with recurrent infection the majority (n=22, 92%) had growth 
of strong biofilm producers. A statistically significant association between 
recurrent infections and strong biofilm producers, and vice versa, between 
resolved infections and non/weak producers, was found (p=0.011) (Paper I, 
Figure 4B and 4C).  
 
A greater probability of infection recurrence was observed in patients who had 
been infected by strong biofilm producers, with Odds Ratio 5.5 (95% C.I. = 
1.65-18.44, p=0.008).  
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Biofilm production and infection relapse 
 
Bacterial strains had been isolated and saved from subsequent surgery for 12 
of the 24 patients with recurrent infection and these were analysed. Six of the 
12 patients had a confirmed infection relapse (Paper I, Supplementary material, 
Table S3). Relapses were more often caused by strong biofilm producers 
(n=5). Further, they were more common in patients with implant preserving 
surgery (Paper I, Figure 5A).  
 
Biofilm susceptibility and its relation to clinical outcome 
 
MBEChigh was more frequent in patients with recurrent infection and MBEClow 
more frequent in resolved infections (Paper I, Figure 5B). However, this was 
not of statistical significance. No statistically significant association between 
MBEChigh or MBEClow and clinical outcome could be observed (p=0.3).  
 
Comparisons of MBEC and MIC showed that the absolute values of MBEC 
were significantly higher than MIC for all antimicrobial agents (Paper I, Figure 
6). For most antimicrobial agents the antibiogram patterns differed when 
susceptibility was tested according to MIC and MBEC (Paper I, Figure 7), and 
more strains were categorised as resistant according to MBEC compared to 
MIC. Oxacillin (OXA) has the most similar susceptibility pattern when 
comparing MIC and MBEC susceptibility.  
 
The MBEC/MIC-ratios were calculated for each antimicrobial agent to 
illustrate the increase of antimicrobial dose needed for eradication of biofilm 
growth compared to planktonic growth. The absolute values for MBEC were 
divided by the values for MIC. The median MBEC/MIC-ratio was lowest for 
RIF (ratio: 2) and highest for VAN and FA (ratio: 128) (Paper I, Figure 6). 
There were some intra-species differences in regard of MBEC where S. 
epidermidis required higher MBECCIP than other CoNS, and S.aureus required 
highest MBECOXA compares to S. epidermidis and other CoNS (Paper I, Figure 
8A).  
 
Other than for CIP, no statistically significant difference could be observed for 
biofilm production category and MBEC/MIC-ratios. For CIP, the 
MBEC/MIC-ratios for non/weak producers was 99 compared to strong 
producers with 360 (p=0.037). When biofilm production was split into further 
groups (non-, weak, moderate and strong), higher MBEC/MIC-ratios were 
observed in strains producing biofilm (weak, moderate and strong) compared 
to non-biofilm producers (Paper I, Supplementary material, Figure S4). 
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When MBEC/MIC-ratios were compared to clinical outcome, MBEC/MIC-
ratios for OXA were significantly higher in recurrent infections compared to 
resolved infections (p=0.01) (Paper I, Figure 6). No interaction between 
biofilm production and MBEC/MIC-ratios on clinical outcome was observed.   
5.2 PAPER II 
 
Study population 
 
Using the SHAR, 2,571 DAIR reoperations in 1,692 patients were identified 
for the given study period. The supplementary questions for 1,182 (69.9%) of 
these patients were collected and 42 of 64 (66%) of the Swedish orthopaedic 
units participated. After study exclusion, 575 patients were eligible for further 
analysis (Paper II, Figure 1).   
 
The exchange and non-exchange group had similar demography (Paper II, 
Table I). Symptom onset from primary surgery differed the greatest where 
73.4% of the exchange group had symptoms within 30 days of their surgery 
compared to 66.8% in the non-exchange group. In regard of surgical technique 
for DAIR with exchange, the femoral head was exchanged in the majority of 
cases (n=297, 81.6%) compared to the exchange of both the femoral head and 
acetabular liner (n=67, 18.4%) (Paper II, Supplementary Table 1).  
 
DAIR with exchange and non-exchange DAIR 
 
In the entire cohort of 575 patients, 195 (33.9%) patients had further surgery 
after their first DAIR procedure (Paper II, Table 2). The only cause for further 
reoperation within two years was recurrent PJI. Multiple procedures (>1) were 
conducted in 111 (19.3%) patients (Paper II, Table 2). It was more common 
that patients who had undergone non-exchange DAIR were made subject to 
more than one subsequent procedure (n=57, 27%) compared to DAIR with 
exchange (n=54, 15%). Furthermore, the mortality rate was 12.8% in the non-
exchange group compared to 8.0% in DAIR with exchange. 
 
DAIR with exchange of modular components was more successful than non-
exchange. The reoperation rate for DAIR with exchange was 28% compared 
to non-exchange at 44%. The difference between the procedures was reflected 
in the Kaplan-Meier implant survival estimate for which DAIR with exchange 
was 71.4% (95% C.I. = 66.9%-76.3%) compared to non-exchange 55.5% (95% 
C.I. = 49.1%-62-7%) (Paper II, Figure 2). In a univariable analysis, DAIR with 
exchange implied a significant risk reduction for further surgery with HR 0.52 
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(95% C.I. = 0.39-0.68). This risk reduction persisted in the multivariable 
analysis with HR 0.51 (95% C.I. = 0.38-0-68) (Paper II, Table 3).  
Patients with S. aureus/S. lugdunensis infections had a higher risk of recurrent 
infection compared to CoNS (Paper II, Table 3). No other variable was 
associated with an increased risk for subsequent surgery. Neither was ASA-
class in the sensitivity analysis (Paper II, Supplementary material, table 2).  
DAIR and subsequent revision of bone-anchored components due to 
infection 
Overall, 92 (47.2%) of the 195 patients had a following revision procedure 
after their DAIR (Paper II, Table 2). Revision was more common in patients 
who had undergone non-exchange DAIR (20.4%) compared to DAIR with 
exchange (13.5%) (Paper II, Table 2). Complete extraction was the most 
frequent type of revision procedure across both groups. The Kaplan-Meier 
survival estimate was 86.1% (95% C.I. = 82.4%-89.8%) for DAIR with 
exchange compared to non-exchange at 78.8% (95% C.I. = 73.3%-84.6%) 
(Paper II, Figure 3). The risk of revision was lower after DAIR with exchange 
compared to non-exchange, HR 0.61 (95% C.I. = 0-41-0.92), when unadjusted. 
Adjusted, there was no statistical significance in risk reduction (Paper II, 
Supplementary Table 3).  
Analysis of true infection resolution 
In the sub-group population (n=151) in which detailed information on 
infection status was available, 83 (55%) of the patients had a 
resolved infection. DAIR with exchange was more successful with infection 
resolution in 61.3% of the cases compared to 42.6% in the non-exchange 
group. Of the non-resolved infections, four (5.8%) patients did not undergo 
further surgery meaning that the use of reoperation as a marker for recurrent 
infection failed to capture these (Paper II, Table 4).  
Antimicrobial treatment 
Patients were given antimicrobial treatment prior to their DAIR procedure in 
39% of the cases (Paper II, Table 5). Combinations of RIF in polytherapy 
were more frequently used in patients in the DAIR with exchange group. 
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5.3 PAPER III 
 
Study population 
 
A total of 1654 patients were eligible for the study. Demographically, the one- 
and two-stage groups differed in age, time from primary procedure to revision 
surgery and follow-up time (Paper III, Table 1).  
 
Distribution of method use 
 
The majority of revision procedures were conducted as two-stage procedures 
(n=1250) and the remaining were one-stage procedures (n=404). The 
employment of revision methods changed during the study period where the 
one-stage procedure was the most common during the first 10 years (used in 
59.4% of cases), and the two-stage dominated the last 25 years (used in at least 
80% of cases) (Paper III, Table 2 and Figure 1). 
 
Re-revision due to all causes 
 
In the one-stage and two-stage groups 83 (21%) and 259 (21%) were re-
revised, (all causes for revision), after their first revision. Unadjusted, the 
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Re-revision due to aseptic loosening 
 
For re-revision due to aseptic loosening, no difference in implant survival 
could be found between the one- and two-stage method (p=0.9) (Paper III, 
Figure 4). There was no difference in risk for re-revision when comparing the 
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Sensitivity analysis for re-revision due to all causes 
In total, ASA-class was available for 466 patients. In this cohort, no difference 
in re-revision could be found between the two revision methods when ASA-
class and year of surgery was added in the regression analysis, HR=0.7 (95% 
C.I.=0.3-1.6, p=0.4). The distribution of ASA-class and BMI was similar in
both groups (Paper III, Table 3).
5.4 PAPER IV 
Study participants were between 40 and 74 years old and the majority were 
male (78%) (Paper IV, Table 1). Several feelings, mainly negative, were 
reported when surgeons reflected upon how PJI affected them emotionally 
(Figure 23).  
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Figure 23.  The feelings reported by surgeons when reflecting upon how PJI affected 
them emotionally.   
Four main themes were identified in this study: the challenging road towards 
a diagnosis, tailoring a treatment plan, the relationship between surgeon and 
patient, and caring for patients with PJI (Paper IV, Figure 2 and 3). 
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THE CHALLENGING ROAD TOWARDS A DIAGNOSIS 
 
Difficulties in verifying the infection and conveying the diagnosis 
 
”There are many unsatisfied patients with pain. Which one of them have an 
infection?”   
Surgeon (P11) 
 
Low virulent infections were most difficult to detect and diagnose due to 
diffuse symptoms and inconclusive blood samples. Diagnostic tools were 
unreliable, and surgeons felt frustrated when their clinical suspicion could not 
be objectively verified. Improved microbiological methods for determining 
culture growth contributed to better diagnostics, but also posed a difficulty in 
determining causative bacteria. This further highlighted the importance of 
adequate sampling and being able to trust the microbiological department.  
 
”The difficulties arise in low-virulent strains when diagnostic cultures are 
inconclusive and one is left without aetiology. You then either fumble or wait and 
repeat the [diagnostic] procedures several times, or you initiate a treatment without 
valid foundation.”   
Surgeon (P15) 
 
Making the decision and conveying it 
 
Deciding upon infection was tough considering the consequences for the 
affected patient. Surgeons did not unnecessarily want to scare their patient 
when informing them of suspected PJI and sometimes they withheld how great 
their suspicion was. Diagnostic uncertainty generated the feeling of frustration 
and sometimes insufficiency. Thus, although they were aware of the 
implications for the affected patient, some felt relief once PJI was confirmed. 
 
Managing uncertainty and the emotional impact of diagnostic difficulties 
 
Being responsible for an inconclusive investigation left the surgeon feeling 
frustrated and insecure. Many relied on their previous experiences, consulted 
more experienced colleagues or contacted other orthopaedic departments to 
manage uncertainty. All study participants highlighted the importance of a 
multi-disciplinary approach with infectious disease (ID) specialists during 
diagnostics. Surgeons also found it important to involve the patient in the 
further investigation. 
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Accepting the diagnosis – a change of attitude 
A greater acceptance and awareness for PJI was described today compared to 
the past. The informants themselves were much more active and persistent in 
the diagnostics and management of PJI compared to their previous approach 
to it. However, surgeons admitted that it was difficult to get over the threshold 
of acceptance of PJI, this was most difficult early on in the surgeon’s career. 
Once over the threshold of acceptance though, surgeons more likely had PJI in 
mind as a differential diagnosis moving forward. 
"It’s difficult to accept that something you do can become infected; accepting it is 
almost like dealing with grief.”  
Surgeon (P4) 
TAILORING A TREATMENT PLAN 
Balancing the patient’s conditions and needs with treatment options 
Several factors were considered when planning treatment. The most important 
was to patient-centre treatment and create individualized plans. Sturdier 
evidence and clear treatment algorithms were warranted as treatment opinions 
could vary within one clinic. Two surgeons described decision-making as 
rather easy as they felt that treatment was more or less standardized. 
Choice of revision method was based on the surgeon’s method of preference, 
the unit’s tradition, what the surgeon had been educated in and what he or she 
thought would give the best end result. All but one said that they preferred and 
utilized the two-stage method. The surgeon’s preferred method was most often 
used.  
“Sometimes I almost immediately feel that it’s better for the patient to have a two-
stage revision, or at least it makes me feel more secure.”  
Surgeon (P6) 
Many liked the thought of the one-stage procedure but wanted more evidence. 
The surgeon who used the one-stage method felt it was easier to take care of 
patients as he/she could offer a less burdensome treatment method.  
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Planning the treatment and complicating factors 
Surgeons could feel stressed by the inability to offer the patient a clear 
treatment plan early on. Sometimes patients met different colleagues with  
different treatment opinions. The informants emphasized the need for 
continuity in order to avoid confusion and patient insecurity.  
“This is a patient who is particularly vulnerable and very exposed; a patient like this 
requires involvement and continuity… The worst thing is when these patients are 
passed back and forth between colleagues who have different opinions. That creates 
a huge sense of insecurity.”  
Surgeon (P1) 
Furthermore, lack of time posed a difficulty in planning PJI treatment and led 
to the re-scheduling of elective surgery to make room for PJI patients. The 
snowball effect of this was frustrating and stressful. Also, lack of time slots 
prolonged time to adequate treatment, putting some patients at risk for failed 
treatment or the development of sepsis.  
Everyone agreed on the importance of team work and multi-disciplinary 
collaboration to optimize treatment. Working together with infections disease 
(ID) specialists was especially important and considered essential to provide 
the best possible care. However, mistrusting the ID specialist was reported and 
one surgeon by-passed his/her local ID specialist and contacted the regional 
hospital for advice. 
“In the past, patients were passed back and forth between the orthopaedic clinic and 
the ID clinic, as no one wanted to take responsibility for the infection.”  
Surgeon (P7) 
Surgeons felt insecure being responsible for the prescription of antimicrobial 
treatment due to their interactions with other medications and gruesome side 
effects. Again, the importance of collaboration with ID doctors was brought 
forth. One surgeon claimed that patients found the antimicrobial treatment 
more dreadful than living without a prosthesis. The possibility to give patients 
prophylactic anti-depressants during treatment was brought forth.  
Maintaining the patient’s faith in treatment was difficult as surgeons also 
reported on the fear of persistent infections. Further, the uncertainty of 
treatment outcome was described as distressing and actual failure was 
associated with disappointment, worry and frustration. 
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“When patients suffer mentally it also affects the doctor in the role of being positive, 
supportive and having a professional approach”  
Surgeon (P12) 
 
THE RELATIONSHIP BETWEEN SURGEON AND 
PATIENT 
 
Preparing the patient for what lies ahead and understanding his or her 
needs 
 
Despite pre-operative information, surgeons were aware that patients did not 
expect PJI. They also acknowledged the huge adaption patients needed to go 
through during treatment and highlighted the need for continuity of a 
committed and responsive team. Although all surgeons agreed on its 
importance, continuity was near impossible to achieve because of the rotational 
nature of the staff schedule. 
 
“Patients are put in a challenging situation when they have been expecting the 
operation to be successful and it isn’t.”  
Surgeon (P10) 
 
All agreed that it was important that the patient participated in their care and 
treatment planning. Also, it was important that the patient understood that the 
infection was not their own fault. Mediating hope but at the same time realistic 
expectations on subsistence during treatment was described as difficult. The 
prerequisites for a good patient meeting involved being able to set aside time 
to listen. However, lack of sufficient time during patient visits aggravated this.  
 
”I think continuity is more important, that the same doctor is responsible for the 
treatment and the entire process. As far as the patient is concerned, this is far more 
important than who wields the knife.”  
Surgeon (P11) 
 
Offering patients the possibility to meet a welfare officer was considered 
important. Surgeons wanted to support their patients as much as possible and 
being able to show support gave the surgeon a feeling of being useful. They 
also wanted to be personal but wanted to be professional at the same time when 
meeting an upset or sad patient. By referring the patient to a welfare officer the 
surgeon could protect him- or herself from getting too emotionally involved.  
 
”There’s plenty of scope for feelings of guilt for both the patient and the doctor”  
Surgeon (P4)  
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The impact of the patient – surgeon relationship 
 
Surgeons described a special type of relationship with PJI patients since they 
got to know them and their related rather well. Finding solace in the patient 
meeting was described, if the surgeon had a good relationship with their 
patient. Many patients showed an understanding for the multi-factorial genesis 
in PJI, however, some blamed their surgeon for it. Some patients requested 
referrals to the regional hospitals as they believed that their surgeons were 
better.  
 
Surgeons felt sad and disappointed when one of their “own” patients was 
infected. They often felt they had done everything in their power to prevent 
PJI. A couple of surgeons described PJI in their “own” patient as a personal 
failure and a defeat. Some worried about how to maintain their patient’s trust 
in the event of PJI. 
 
Taking care of a referred patient was easier as surgeons did not need to feel as 
guilty or feel that they had made a bad decision about an operation that had 
failed. However, the surgeon could feel worried that he or she would not be as 
committed when taking over someone else’s patient as he or she did not have 
an existing relationship with that patient. 
 
”It’s slightly easier to take over other people’s patients, as you know that you don’t 
need to feel guilty about being involved in something that went wrong.”   
Surgeon (P17) 
 
CARING FOR PATIENTS WITH PJI 
 
The feeling of guilt 
 
Many brought up the feeling of guilt and felt accountable for PJI describing 
the feeling of personal failure. Surgeons were aware of the multi-factorial 
causes of PJI but as one surgeon said: “you take the blame anyway”. Patients 
and their related could perceive PJI as the surgeon’s failure. The accusative 
attitude was sometimes difficult to manage and when in despair patients could 
take it out on the surgeon. In such situations, surgeons desired support from 
their colleagues. However, most often, the patients did not seek a scapegoat.  
 
“What I sometimes find most difficult is relatives who are very obstinate and 
somewhat accusatory when there’s a feeling that it’s our fault... What did you do 
wrong, have you made a mistake?”  
Surgeon (P1) 
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Surgeons said that it was important to be unpresuming and scrutinize one’s 
role in the process. Some meant that PJI was inevitable. Surgeons questioned 
themselves, ruminated on cases, tried to identify what they could have done 
better and reflected upon the cause of PJI cases, even at home, but not to the 
extent that it affected their ability to sleep. At times the surgeon could feel 
worried if her or she got a feeling that he or she could have done something 
better. 
 
”It is a difficult diagnosis and you find yourself ruminating a bit about your patients 
with prosthetic joint infections all the time”  
Surgeon (P18) 
 
Coping with difficult feelings and the need for emotional support 
 
Surgeons found it important to learn how to emotionally deal with 
complications in order to prevent burn-out. This became easier with 
experience. Surgeons highly valued the emotional support they received from 
their colleagues. Being part of a social environment open for discussions to 
avoid dealing with PJI cases alone was described as important. One surgeon 
had experienced handling PJI on his or her own and felt that this had been very 
difficult. Many felt that the collegial support was sufficient and sufficed as 
debriefing. However, some, mainly at the regional hospital, desired structured 
support with the possibility for external support and reflected upon the lack of 
support available for doctors, e.g. that debriefing opportunities were not given 
to doctors after adverse events, but were offered to other health care staff. One 
surgeon described how he/she shut down emotionally so that the situation 
would not get too personal. Further, the importance of multi-disciplinary 
collaboration was mentioned by all study participants. Also, for support and 
for educational reasons, it was considered good that a team consisted of 
surgeons with a mix of experience. 
 
”Having a good relationship to your colleagues, helping each other out and talking 
to each other about complications is the salvation. The support you get from your 
colleagues makes the work situation much more sustainable.” 
Surgeon (P9) 
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Figure 24. The importance of a multi-disciplinary collaboration, discussing cases 
with colleagues and being able to turn to experienced colleagues for advice was 
highlighted by study participants (from the left: clinical microbiologist, infectious 
disease specialist, orthopaedic surgeon 1, orthopaedic surgeon 2, experienced 
prosthetic joint surgeon 1, experienced prosthetic joint surgeon 2. 
Acceptance of PJI was most difficult early on in the career. At the beginning 
of their career surgeons were more inclined to self-blame, consider PJI as 
“hopeless”, and reported on the difficulty in realizing the magnitude of PJI. 
They also mentioned troubles sleeping and worried about treatment choices 
and not being able to help their patient. With experience it became easier to 
manage patients with PJI as the surgeons knew roughly how the outcome 
would be and could rely on their previous experiences of PJI and better trust 
their judgement. However, experienced surgeons could also feel worried.  
“The more experienced you are, the more frightened and more careful you are when 
you meet an infected patient”  
Surgeon (P11) 
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MOVING FORWARD 
 
The organization of PJI management differed at the surgeons’ units but several 
structural improvements were mentioned as suggestions on facilitating factors 
during management (Paper IV, Figure 4).  
 
To detect PJI surgeons desired standardized follow-up of patients; clear 
referral paths for GPs; better educated GPs, medical locums, junior doctors and 
emergency room doctors. Surgeons were concerned about the change of 
expertise in the hospital’s emergency room as it nowadays most often was 
staffed by emergency doctors and junior doctors.  
 
Surgeons wished for an even better collaboration between colleagues, 
committed ID specialists and the microbiological laboratory. Surgeons who 
worked at units without joint out-patient appointments with ID specialists 
wanted such a set-up.  
 
Some surgeons discussed centralizing the care of PJI, meaning that it would 
maybe make the surgeons who work there much better experienced. In turn, 
other surgeons would then be able to consult them for help in the management 
of PJI. With a dedicated center, inexperienced surgeons would not need to deal 
with PJI and thereby not need to feel worry or a sense of personal failure 
otherwise associated with PJI. However, there was a fear that well-functioning 
smaller centres would lose their abilities to treat PJI.  
 
Sometimes patients were kept at the hospital ward for a long time, often due to 
intravenous antimicrobial treatment. Administering antibiotics at home was 
described as a solution to this problem. 
 
At smaller hospitals the geographical distances from patient to hospital could 
be very big and made it harder to follow the patient after discharge from the 
hospital. One surgeon highlighted the wish for better follow up routines in such 
cases.  
 
Many felt that it was difficult to maintain continuity with today’s organization 
of the health care system. Some felt that there was not always enough 
understanding from the clinic or health care system for PJI. The surgeon had 
to work hard to be able to schedule PJI patients and sometimes persuade the 
ward staff that the patient needed a longer in-house stay. At clinics where PJI 
was prioritized which made it easier for the surgeon.  
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Figure 24. The importance of a multi-disciplinary collaboration, discussing cases 
with colleagues and being able to turn to experienced colleagues for advice was 
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prosthetic joint surgeon 1, experienced prosthetic joint surgeon 2. 
Acceptance of PJI was most difficult early on in the career. At the beginning 
of their career surgeons were more inclined to self-blame, consider PJI as 
“hopeless”, and reported on the difficulty in realizing the magnitude of PJI. 
They also mentioned troubles sleeping and worried about treatment choices 
and not being able to help their patient. With experience it became easier to 
manage patients with PJI as the surgeons knew roughly how the outcome 
would be and could rely on their previous experiences of PJI and better trust 
their judgement. However, experienced surgeons could also feel worried.  
“The more experienced you are, the more frightened and more careful you are when 
you meet an infected patient”  
Surgeon (P11) 
  5 RESULTS 
69 
MOVING FORWARD 
 
The organization of PJI management differed at the surgeons’ units but several 
structural improvements were mentioned as suggestions on facilitating factors 
during management (Paper IV, Figure 4).  
 
To detect PJI surgeons desired standardized follow-up of patients; clear 
referral paths for GPs; better educated GPs, medical locums, junior doctors and 
emergency room doctors. Surgeons were concerned about the change of 
expertise in the hospital’s emergency room as it nowadays most often was 
staffed by emergency doctors and junior doctors.  
 
Surgeons wished for an even better collaboration between colleagues, 
committed ID specialists and the microbiological laboratory. Surgeons who 
worked at units without joint out-patient appointments with ID specialists 
wanted such a set-up.  
 
Some surgeons discussed centralizing the care of PJI, meaning that it would 
maybe make the surgeons who work there much better experienced. In turn, 
other surgeons would then be able to consult them for help in the management 
of PJI. With a dedicated center, inexperienced surgeons would not need to deal 
with PJI and thereby not need to feel worry or a sense of personal failure 
otherwise associated with PJI. However, there was a fear that well-functioning 
smaller centres would lose their abilities to treat PJI.  
 
Sometimes patients were kept at the hospital ward for a long time, often due to 
intravenous antimicrobial treatment. Administering antibiotics at home was 
described as a solution to this problem. 
 
At smaller hospitals the geographical distances from patient to hospital could 
be very big and made it harder to follow the patient after discharge from the 
hospital. One surgeon highlighted the wish for better follow up routines in such 
cases.  
 
Many felt that it was difficult to maintain continuity with today’s organization 
of the health care system. Some felt that there was not always enough 
understanding from the clinic or health care system for PJI. The surgeon had 
to work hard to be able to schedule PJI patients and sometimes persuade the 
ward staff that the patient needed a longer in-house stay. At clinics where PJI 
was prioritized which made it easier for the surgeon.  
 
  5 RESULTS 
70 
There was a need for more time to manage PJI patients. Fully-booked 
appointment schedules and operation schedules made it difficult and stressful 
for the surgeons to find the time for PJI patients. It was described as difficult 
and challenging to keep focus and maintain an optimal standard when the 
surgeon had to work after hours on PJI cases. Sometimes the lack of time meant 
that the surgeon could not think through the management plan thoroughly 
enough which sometimes led to hasty decisions. 
 
As mentioned, many felt that the support from their colleagues was sufficient. 
However, some wished for more structured support and having set times in the 
schedule for case discussions was brought up as a desired for improvement.   
 
The lack of evidence for new methods was described as problematic as they 
were sometimes introduced in a non-evidence-based matter. Surgeon was 
worried that the companies behind the technological advances did not 
understand the full problem of PJI. Also, as a surgeon it felt impossible to 
understand which systems were the best 
 
ADDITIONAL RESULTS 
 
Surgeons felt that they were better at registering procedures in the SHAR 
nowadays leading to an increased trust for reports on infection. Further, 
improved diagnostic methods led to better detection of PJI, also contributing 
to more reliable statistics. However, this also meant that it made it difficult to 
compare incidence rates over the years.  
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6 DISCUSSION 
6.1 PAPER I 
Biofilm production and clinical outcome 
In the current study, presence of a strong biofilm implied a greater risk of, and 
was associated with, treatment failure. In contrast, non/weak biofilm 
production was associated with infection resolution. This is the first study to 
investigate the influence of biofilm production on clinical outcome, i.e. 
infection status, in a study cohort of only PJI patients. In a non-orthopaedic 
setting the effect of biofilm production on clinical outcome is ambiguous. 
Biofilm production in S. aureus causing bacteraemia has not been associated 
with poor clinical outcome (bacteraemia, endocarditis or death).202 However, 
biofilm forming strains have been reported more common in patients with 
persistent infections,203 and another study linked biofilm production to 
persistent skin and soft-tissue infections in trauma injuries in military staff.204 
Within orthopaedic infections, strong biofilm has been associated to greater 
treatment failure. Morgenstern et al. investigated biofilm production caused by 
S. epidermidis after fracture osteosyntheses and PJI, and concluded that strong 
biofilm production gave a lower rate of treatment success compared to non-
biofilm producers.205 In their study, non-biofilm production was associated 
with cure rates of 85% whereas the strongest biofilm producers had a cure rate 
of 60%. A lower cure rate was also found by Post et al. in orthopaedic device-
related infections caused by strong biofilm producers compared to non-
producers.206 Furthermore, Zaborowska et al. reported on a worse clinical 
outcome in percutaneous orthopaedic implant infections caused by strong 
biofilm producers.58 Overall, the studies on biofilm production in relation to 
clinical outcome are difficult to compare to one another as factors such as 
inclusion of bacterial species, biofilm quantification methods, type of 
infection, definitions for biofilm production and outcome definitions differ. 
Nonetheless, the current study adds on to research suggesting that biofilm 
production has an influence on clinical outcome and should be assessed in the 
management of PJI.206-208
The majority (73%) of bacterial strains in the current study showed strong 
biofilm production ability. The ability of staphylococci to produce biofilm has 
previously been reported.127, 206, 207 Biofilm production was evaluated per 
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species to identify whether biofilm production was greater in S. aureus, S. 
epidermidis or the other CoNS species. Strong biofilm producers were more 
frequent than non/weak producers across all three species groups. In the group 
of other CoNS (n=8), of which there were five S. capitis, there were no 
non/weak producers. This may be a random finding, but S. capitis has recently 
been suggested as an emerging nosocomial pathogen in PJI displaying biofilm 
production abilities.209 
 
The association between biofilm production, MBEC and clinical 
outcome 
 
The primary and secondary outcome of the current study was to evaluate the 
relationships between biofilm production, MBEC and clinical outcome. It can 
be hypothesized that MBEC could be used as a surrogate marker for biofilm 
production (Figure 25). The current study could establish an association 
between biofilm production and clinical outcome. However, no association 
could be found between biofilm production and MBEC, or MBEC and clinical 
outcome. 
 
Figure 25. The hypothesized relationship between biofilm production, MBEC and 
clinical outcome.  
 
The absence of an association between MBEC and clinical outcome could be 
explained by two factors. Firstly, MBEC for the most potent antimicrobial 
administered was not available for all cases. The MBEC of seven cases could 
not be compared to clinical outcome due to this missing data, limiting the study 
sample size. Secondly, the assignment of several of the bacterial strains from 
the same infection to the same clinical outcome, despite intra-species 
variations of MBEC, may further obstruct an identification of association.  
 
 
MBEC 
BIOFILM 
PRODUCTION 
CLINICAL 
OUTCOME 
6 DISCUSSION 
73 
Biofilm susceptibility 
Antimicrobial concentrations in the tissue of the affected joint are unknown 
and there is a risk that treatment guided with MIC leads to sub-inhibitory 
antimicrobial concentrations in tissue. Mlynek et al. found that the exposure 
of MRSA to sub-MICs of amoxicillin induced surface adhesion and biofilm 
production.210 Further, bacterial strains were up to 8,192 times more resistant 
to antimicrobials when grown in biofilms compared to their planktonic state in 
the present study. This finding confirms previous research reporting on a 
greater resistance of biofilm versus planktonic when comparing MBECs to 
MICs.56-58, 134, 207, 208 This implies that MIC-guided antimicrobial treatment 
reflects the planktonic state of bacteria but does not consider susceptibility 
when bacteria are adherent and grown in biofilm. This further suggests that 
MICs may be insufficient in guiding antimicrobial treatment in biofilm-
associated infections, which should be considered when administering 
antimicrobial treatment.  
Patients in the current study were treated with intravenous vancomycin (mono- 
or polytherapy) in the majority (71%) of cases. However, in the current study, 
vancomycin was also associated with the greatest median MBEC/MIC-ratio.  
MBECVAN was greater than MICVAN for 77% of the strains. The resistance to 
vancomycin in biofilm- producing staphylococci has previously been 
confirmed in a study where 93% of biofilm producers were non-susceptible.208 
Rifampicin in combination therapy was the most common oral antimicrobial 
treatment, used in 69% of cases. In terms of susceptibility, rifampicin was the 
most susceptible option when comparing MBEC/MIC-ratios as 46% of 
MBECsRIF were equivalent or lower than MICsRIF. Thus, our results confirm 
rifampicin as the best oral option.32, 211 The high MBEC/MIC-ratios and the 
antibiogram patterns for both vancomycin and rifampicin may further indicate 
that treatment guided by MIC is insufficient.212  
The concentrations of antimicrobial agents needed to eradicate bacteria using 
doses guided by MBEC could in many cases imply toxic levels in human 
tissue. As such it may not be a useful addition in regards of dosage guidance. 
However, using MBEC as a tool to evaluate the empiric biofilm susceptibilities 
of causative bacteria may, nonetheless, be advantageous in the early decision-
making on surgical options.  
Cell numbers were equal in the starting bacterial inoculums used for MIC and 
MBEC determination. Therefore, the higher resistance of MBECs cannot be 
explained by a high cell count as biofilm production was not dependent of 
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explained by a high cell count as biofilm production was not dependent of 
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inoculum size. Instead, the actual switch of growth into a state of biofilm 
explains the greater resistance, also suggested by Zaborowska et al.58  
 
C-reactive protein and biofilm production  
 
Patients with recurrent infection had a higher median CRP compared to 
patients with infection resolution. CRP has previously been suggested as a 
good surrogate marker for the size of bacterial infectious dose which in turn 
may affect the efficacy of antimicrobial treatment.38 Although the range of 
CRP (2-450) was greater in patients with strong biofilm producers compared 
to non/weak (3-170), the median remained similar between the groups. CRP 
over 115 mg/L is associated with failure in DAIR treatment,38, 154 however, it 
is unknown if failure is due to biofilm production and whether CRP is 
associated with biofilm. Further studies are needed to establish the relationship 
between CRP and biofilm production.  
 
Strengths, limitations and methodological considerations? 
 
This study is the first to evaluate staphylococcal biofilm in a cohort of only PJI 
patients in relation to clinical outcome. It employs a method for detection of 
biofilm (CV) which is easily adaptable in clinical laboratories whilst both time- 
and cost efficient. Further, it confirms that biofilms are more resistant to 
antimicrobials when MBEC is used compared to MIC which may be an 
important clinical factor when deciding upon antimicrobial treatment. The lack 
of association between MBEC and clinical outcome may be due to sample size.  
 
The storage and transportation of the bacterial strains may have affected their 
virulence properties. Bacterial strains were stored at -80 °C and should tolerate 
1-10 years in these conditions whilst maintaining their virulence factors.192 The 
different phase variants of biofilm are noteworthy when preparing 
staphylococcal inoculum. There are several ways to measure biofilm biomass, 
the current study used CV which is commonly used, 213 however the metabolic 
activity of the biofilm was not evaluated and could be considered a good 
supplement in further studies on biofilm susceptibility. However, in a clinical 
setting the detection of whether biofilm is present or not and its metabolic state 
in the patient is unknown and for this CV can be used on its own.  Manual 
reading of the OD is user dependent and an automatic reader may minimize 
analyst bias.  
 
The results of the current study could have been affected by another 
classification of biofilm production such as using the Stepanovic et al.192 
classification instead of Baldassarri et al.193 Further, Post et al. defined patients 
as cured if they were infection free at a defined follow-up time regardless of 
  6 DISCUSSION 
75 
whether multiple surgical procedures had been conducted along the way.206 
Such a definition may have altered our results. We have used the clinical 
breakpoint designed for MIC for both MIC and MBEC. However, there is no 
clinical breakpoint for MBEC, nor a standardized test medium, perhaps due to 
differing nutritional needs to stimulate biofilm growth in vitro. 
 
MBEC can vary slightly in definition but, defined as the complete biofilm 
bactericidal concentration, additional measurements of CFU counts need to be 
done as there is a lower limit in detection level of viable cells in our model.214 
In our model the biofilm-coated pegs were exposed to the antimicrobial agents 
for 18-20 h and thereafter exposed to a neutralizing agent during 24 h in which 
any viable cells were able to grow. In that aspect, the MBEC values we 
determined should be the correct eradication values if no turbidity was 
measured. Both MIC and MBEC values were determined by visual inspection 
of the first non-turbid concentration, makes them equivalent and comparable.  
 
An alternative model of analysis could have been the employment of a worst-
case model in which the strain with greatest biofilm production was selected 
for further analysis. However, regarding the infection as an entity of all the 
strains found in the same samples, our approach may be justified as there may 
be synergistic effects contributing to infection.54 Hence, it would be interesting 
to further elucidate the  relationship between biofilm production, MBEC and 
clinical outcome (Figure 25) in another cohort including only single strain 
infections and in which MBEC to the administered antimicrobial treatment was 
available for all infections. 
 
The findings of the current study should be interpreted in the light of its in vitro 
setting. Although the CBD is an acknowledged model of biofilm 
quantification, the peg lids are not comparable to prosthetic material and the 
test mediums do not reflect the in vivo setting. Several actions can be taken to 
further mimic the in vivo conditions of the host tissues and immune response 
such as coating of the pegs and the use of medium resembling host conditions. 
The use of simulated synovial fluid as test medium may be a good alternative 
and  has been found to better stimulate biofilm growth and maturity compared 
to TSB and serum.127 Such actions may enhance the models and contribute to 
a greater transferability.  
 
Clinical implications 
 
The current study reports on an increased risk of infection recurrence in the 
presence of strong biofilm producers. Thus, additional reproducible methods 
of biofilm evaluation, such as the microtiter plate test (crystal violet), may 
facilitate the routine diagnostics of PJI. Biofilm production may have a 
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predictive value but the association of biofilm production on clinical outcome 
needs to be further evaluated in larger study cohorts.  
 
6.2 PAPER II  
 
Exchange or non-exchange? 
 
The overall success rate of both DAIR methods combined was 61.1% which 
lies within the span of previously reported numbers of 26.9-87%.15, 34, 137-139, 141 
DAIR with exchange had a higher success rates than non-exchange DAIR and 
implied a significant risk reduction for further surgery. The current study is the 
largest study on first-time PJI after primary THA and its result confirms 
research supporting DAIR with exchange.40, 136, 137, 140 There may be rare 
situations when exchange cannot be conducted due to surgical difficulties. 
However, considering the significant risk reduction for further surgery when 
using DAIR with exchange, it should be employed whenever possible. 
 
The demography of the two treatment groups was similar and could not explain 
the difference in success rates. However, there was a greater proportion of 
patients with symptom onset within 30 days of their primary procedure in the 
exchange group (73.4% compared to 66.8% in the non-exchange group). This 
may influence the greater success rates of DAIR with exchange, as DAIR is 
recommended within 30 days of initial arthroplasty,123 but does not fully 
explain it. Furthermore, time to symptom onset was not a significant 
confounding variable using multivariable regression analysis. Time to onset of 
symptoms is theoretically an important factor in terms of biofilm establishment 
and has been reported a potential indicator of treatment failure, where late 
infection defined as two years after the initial procedure has been associated 
with treatment failure.7 However, time to symptom onset may not affect 
treatment outcome,141 which supports our findings.  
 
Anti-biofilm active therapy, i.e. rifampicin in polytherapy, was more common 
after exchange. We cannot explain the reason for this. However, it may impact 
the success rate in patients undergoing DAIR with exchange as DAIR 
combined with rifampicin in polytherapy is more successful than other 
antimicrobial therapy.211 Length of total antimicrobial therapy differed in the 
two treatment groups. This may also affect treatment success. However, the 
descriptive data on antimicrobial treatment in this study should be interpreted 
with caution. Duration of antimicrobial treatment was pre-defined (Appendix, 
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Supplementary Figure 1) and we only accounted for antimicrobial treatment in 
patients who had not undergone further surgery before hospital discharge. 
 
Another confounder in the success of DAIR, in theory explained by biofilm 
formation, may be the duration of symptoms to surgery. In the current study a 
cut-off of seven days was chosen, as less than seven days symptom duration is 
associated with better outcome.137 No difference in risk for further surgery was 
identified based on symptom duration. Duration of symptoms is an equivocal 
factor, but it is recommended that DAIR should be performed within either 
seven,7 or 21,142 days of symptom onset. Symptom duration of more than seven 
days is associated with DAIR failure.7 In the current study, a further analysis 
for symptom duration <21 days and ≥21 days was conducted. However, no 
difference in risk could be found. 
 
Mortality was higher in the non-exchange group (12.8%) compared to the 
exchange group (8.0%). Non-exchange DAIR may be used in patients where 
more extensive surgery may not be considered suitable. Therefore, it was 
somewhat surprising that the distribution of age and ASA-class were similar 
between both treatment groups. However, the difference in mortality may 
indicate that patients selected for non-exchange had a greater morbidity or 
frailty, making the surgeon more inclined to choose a less extensive procedure 
such as non-exchange DAIR. Even though ASA-class can be used as a measure 
of comorbidity and predictor of mortality,215 it does not consider frailty, the 
assessment is user-dependent and the classification is vague enough to allow 
for several interpretations. Furthermore, there was a greater percentage of 
missing ASA-class in the non-exchange group.  
 
DAIR and revision of bone-anchored components due to infection 
 
The secondary outcome of this study was to analyze the risk of revision of 
bone-anchored components due to infection, as this is a resource demanding 
procedure with considerable impact on the patient’s quality of life. A lower 
percentage of patients undergoing DAIR with exchange had a subsequent 
revision due to infection (13.5%) compared to the non-exchange group 
(20.4%). However, this was not significant in the regression analysis, maybe 
due to a small sample size. Surgeon preference and other factors influencing 
the choice of revision subsequent a single DAIR are unknown and our result 
should be interpreted considering this uncertainty. The impact of a prior DAIR 
on the success of a subsequent two-stage revision is contradictive with reports 
on similar success,216 and lower success217 rates compared to patients who 
undergo staged revision without a prior DAIR.  
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predictive value but the association of biofilm production on clinical outcome 
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Bacterial growth 
 
The type of bacteria may influence treatment results after DAIR. However, this 
needs further elucidation. Some studies have reported on an association 
between CoNS and treatment failure,7, 38 whilst the growth of S. aureus has 
been identified as a risk factor for treatment failure.154 In the current study, S. 
aureus/S. lugdunensis implied a greater risk for additional surgery compared 
to PJI caused by CoNS. Biofilm growth is proposed to be a reason for DAIR 
failure,60 this needs further evaluation in combined in vitro and in vivo studies. 
 
Polymicrobial infections may be more difficult to treat due to possible inter-
microbial synergistic effects and the need for broad antimicrobial treatment.54, 
218 The overall rates of polymicrobial infection for the entire study cohort was 
31.3%, which could have influenced the overall success rates. A previous study 
has reported on rates of polymicrobial infection similar to ours at 38.3%,38 
whereas others reported a lower share (5.5%-13.1% polymicrobial).7, 10, 219  
 
Strengths, limitations and methodological considerations 
 
This is the largest multi-centre cohort study to evaluate the success rate of 
DAIR in first-time PJI after primary arthroplasty. The current study involved 
a retrospective retrieval of data from medical records to gather more 
information on each reoperation. The reporting of data considered the 
suggested “core outcome set” needed for standardizing DAIR research,137 but 
did not include all host status factors, antimicrobial susceptibility or the 
delivery of local antimicrobials. 
 
The data collection form did not include information on infection resolution. 
The end-point of the current study was additional surgery due to PJI and not 
infection resolution. Infection resolution was described for a subset of patients 
in which information on this information could be obtained. In this subset of 
patients  (n = 151), 4 (5.8%) patients had recurrent infection but did not 
undergo further surgery. Hence, using reoperation as a measure of infection 
recurrence captured 94% of all cases. Although this is not valid for the entire 
study population, reoperations can be considered a reasonable way of studying 
recurrent infection. 
 
The current study did not take surgeon experience into account. This may 
affect the results of DAIR. In one study on DAIR of the hip, surgery performed 
by trained hip surgeons showed a greater chance of infection resolution.141 
DAIR with exchange of modular components may require a greater surgical 
experience and therefore suggest the presence of a hip surgeon. Further, the 
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DAIR procedures were not performed according to a standardized protocol and 
as the majority of cases were cemented THA, the liner was not exchanged.  
 
The definition of a successful DAIR varies and some studies evaluate its 
success after multiple consecutive DAIR procedures.34, 40, 220 Considering 
multiple DAIR procedures as a successful therapy would improve the overall 
success rates of the current study. Allowing for two consecutive DAIR 
procedures would increase the overall success rate from 61.1% to 80.3%. It is 
yet unclear how many DAIR procedures are acceptable before resorting to 
revision of bone-anchored components. In a meta-analysis success rates 
improved when multiple debridements were performed, however, this did not 
have statistical significance.137 
 
Clinical implication 
 
The significantly improved success rate compared to non-exchange DAIR 
supports the utilization of DAIR with exchange. DAIR with exchange should 
be conducted whenever possible in attempt to secure the greatest chances for 
infection resolution. Furthermore, our material indicates that success rates 
increase when multiple consecutive DAIR procedures are conducted. A cut-
off for how many consecutive DAIRs are reasonable was not evaluated in the 
current study, but at least a second DAIR may be justified if the first one fails. 
However, this needs further evaluation.  
6.3 PAPER III 
 
Re-revision after one- or two-stage revision 
 
The overall re-revision rates for both methods were 21% in the current study. 
No increased risk for re-revision due to any cause, or specifically due to 
infection or aseptic loosening, could be identified when comparing the one- 
and two-stage methods. This further supports that there may not be a difference 
in infection resolution between the two revision methods.147, 148, 221, 222  
 
There was a difference in age between the patients in the one- and two-stage 
group. Patients in the one-stage group were older than in the two-stage group. 
This could possibly reflect an unwillingness in surgeons to make elderly 
patients subject to two surgeries. 
 
Further, type of fixation differed between the groups. Cemented fixation was 
used to a greater extent during the primary revision procedure in the one-stage 
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This could possibly reflect an unwillingness in surgeons to make elderly 
patients subject to two surgeries. 
 
Further, type of fixation differed between the groups. Cemented fixation was 
used to a greater extent during the primary revision procedure in the one-stage 
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group. This may be due to the age difference as older patients generally receive 
cemented implants. However, in our study the influence of cemented versus 
uncemented fixation is difficult to evaluate. The reason being that the type of 
cement used is not always known and we lack information on use of local 
treatment of antibiotic loaded collagen, calcium sulphate pellets or cement 
beads, which could have influenced the rate of infection resolution. 
 
Strengths, limitations and methodological considerations 
 
This is the largest national observational study on risk for re-revision between 
the one- and two-stage procedure for PJI. A limitation in this study is the lack 
of data on microbiological details and antimicrobial therapy. Unfortunately, 
such data is not available in the SHAR and there are no nationwide registers 
we could have collaborated with to retrieve this information. In two-stage 
revision, staphylococci are associated with a greater risk of recurrent 
infection.223 In one-stage revision, enterococci have been found associated with 
re-revision.224 The lack of microbiological data also obstructs our ability to 
verify whether PJI patients have been diagnosed correctly. Cases diagnosed as 
aseptic loosening may be incorrect. Numbers from recent studies on aseptic 
revisions report that 7-10% are septic and thereby wrongly diagnosed.122, 225 
 
Further, the only variables available on patient related risk factors were ASA-
class and BMI. These were not available for all cases as they were first 
registered in the SHAR from 2008 and onward. To investigate the influence of 
BMI and ASA, a separate sensitivity analysis was performed in which we 
could not find a difference in risk for re-revision. Also, the study period 
stretched over 36 years in which several changes in surgical technique, 
operative hygiene, microbial and antimicrobial development have occurred. 
We included year of revision in the sensitivity analysis to address this and 
could not identify a significant difference in risk for re-revision between the 
one- and two-stage group.   
 
Although nationwide, the current study has not been able to capture all 
revisions and re-revisions due to PJI for the study period. A validation of 
SHAR data from 2005 to 2008, revealed that 78% of the revisions due to PJI 
was reported.226 In addition, it should be noted that our study did not capture 
cases of recurrent infection not treated with further surgery. Hence, there may 
have been cases of recurrent infection where patients were not made subject to 
further surgery. As patients in the one-stage group were older it could be 
assumed that further surgery was abstained to a greater extent in this group.  
 
Addition of microbiological and patient related risk factors would have added 
to the strength of this study. It is, however difficult to study infections using 
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the SHAR without complement from another data source.227 On the other hand, 
the use of register data enables large study cohorts in which “trends” may be 
identified, that could be explored in further research. As such this study adds 
on to existing research and emphasizes the need to further elucidate whether 
the one- or two-stage procedure is superior to the other. 
 
Clinical implications 
 
Several questions regarding the choice of optimal revision strategy are yet 
unanswered and need further evaluation. The current study supports the use of 
one-stage revision as a viable option in PJI treatment. However, the 
aforementioned limitations call for further research to explore if our 
observations remain valid when considering microbial growth, patient 
selection and infection resolution. 
6.4 PAPER IV 
 
The emotional impact of PJI on surgeons 
 
The emotional spectrum of PJI on study participants was largely consistent 
with previous reports on emotional responses to adverse events.177, 228  
Surgeons reported on a four-phase emotional response as identified by Luu et 
al. (Figure 26).186 The phases being i) an emotional reaction to failure, ii) an 
experience of chaos and scrutiny of one’s contribution to the adverse event, iii) 
reflection on what one can learn from the event, iv) the prolonged and 
cumulative effects of one’s emotional response on one’s personal and/or 
professional identity. 
 
The current study illuminates the negative emotional impact of PJI on 
prosthetic joint surgeons. This confirms previous findings of the impact of PJI 
on surgeons.177 Surgeons interviewed in our study were aware of the many 
possible causes leading to PJI and some felt it was irrational that they blamed 
themselves for the infection. Mallon et al. too reported on the accountability 
surgeons felt, but also that surgeons described PJI as inevitable and that they 
did not need feel at fault for it.177 However, there is a report on 80% of 
infections being related to surgery and 20% related to non-surgical factors,86 
and self-scrutiny was reported in our study. 
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Figure 26. The four-phase emotional response in surgeons in the current study, as 
suggested by Luu et al.186  
 
Being recognized as one of the most successful types of surgery, arthroplasty 
surgery may generate another set of expectations and involve a greater 
disappointment from both patient and treating surgeon when it fails. 
Orthopaedic infections, especially PJI, have gained a lot of attention during the 
past years in regards of diagnostics and treatment. Faivre et al. investigated 
burnout nationwide amongst French orthopaedic surgeons and traumatologists 
and found that 39% reported burnout symptoms.229 In addition, 8% reported 
on suicidal thoughts. Further, 43% stated they would not recommend their 
children to follow their career path. Keeping in mind responder bias (response 
rate 23%), the study reports on alarming numbers of psychological ill-being. 
Another study in orthopaedic residents identified medical errors as contributor 
to burnout.230 The current study did not explore burnout (emotional exhaustion, 
depersonalization and low sense of personal accomplishment) as such, but no 
clear signs of it were identified during the interviews. It should also be noted 
that surgeons reported on a positive emotional impact when they were able to 
help their patient and when treatment had been successful. They also described 
finding solace in a good doctor-patient relationship and appreciated the support 
they received from their colleagues.  
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Although the present study is on PJI we believe that the results may be 
applicable on surgeons involved in other types of postoperative infections. The 
magnitude of at which adverse events emotionally affect surgeons in other 
fields has previously been described.180-182, 185, 186, 228, 231  
 
Support needs during the management of PJI 
In the current study, and a UK-based study,177 working with PJI in a team-
based manner was reported as the best measure of professional support. High 
treatment success has been suggested dependent on multi-disciplinary 
collaboration in PJI cases.232 Further, Swedish surgeons regarded the support 
they received from colleagues as the best type of emotional support. Mallon et 
al. described a need for open and regular discussions on adverse, and this too 
was desired by Swedish surgeons.177 The need for support and the possibility 
for discussion has also been emphasized in studies on the emotional response 
to adverse events within other surgical fields.186, 228 Furthermore, there seems 
to be lacking opportunity for surgeons to receive emotional support and discuss 
adverse events and improved emotional support systems have previously been 
warranted.182, 186, 228 
Although surgeons working at county or district hospitals reported conferring 
with their colleagues and with the regional hospitals on PJI cases, surgeons 
working at a regional hospital were more prone to wish for improved peer 
support. They desired regular debriefings or the possibility to talk to an 
external professional to a greater extent than surgeons at non-regional 
hospitals. The fact that complicated cases are referred to the regional hospitals 
may in part explain this. Further, the surgical teams may be bigger at a regional 
hospital which may affect the unity of the group. Nonetheless, the findings 
among UK and Swedish arthroplasty surgeons should encourage health care 
organizations to offer the possibility of structured support and look over 
possibilities to unburden, and facilitate for, surgeons during PJI management. 
The doctor – patient relationship 
 
Surgeons felt worse when “their” patient got infected in contrast to taking over 
“someone else’s” infected patient. Some also worried about maintaining the 
patient’s trust. This worry was confirmed in a study in which patients reported 
on losing faith in their surgeon once infected.6 Andersson et al. confirmed the 
surgeon’s feeling of patients blaming them for the infection, describing a 
bitterness towards doctors.5 Further, patients report on feeling insecure during 
the management of PJI,5 which may be a reflection of the insecurity in 
management reported by surgeons in the current study.  
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patient’s trust. This worry was confirmed in a study in which patients reported 
on losing faith in their surgeon once infected.6 Andersson et al. confirmed the 
surgeon’s feeling of patients blaming them for the infection, describing a 
bitterness towards doctors.5 Further, patients report on feeling insecure during 
the management of PJI,5 which may be a reflection of the insecurity in 
management reported by surgeons in the current study.  
  6 DISCUSSION 
84 
Based on our interviews, we do not think that PJI needs to be diagnosed by a 
colleague to ensure objectivity. However, since the most important factor 
facilitating the surgeon both emotionally and practically was being able to 
discuss PJI cases with a colleague orthopaedic surgeon, that may be an 
incentive to have a colleague involved in the process of diagnostics. Our study 
was based in Sweden where a lot of work has been done to bring awareness to 
infections, also the hospital system is not very hierarchical, which may 
influence a greater openness and reduce factors leading to denial. In other 
countries with other cultures, there may be a greater risk for subjectivity and 
denial. Further, the impact of the doctor-patient relationship may influence 
treatment choice. This was not explored in the current study, but Ryan et al. 
suggested that patients from outside hospitals were more likely treated with 
implant extracting procedures.219 This finding may further support the need for 
collaboration in PJI cases.  
Our study may draw attention to the influence on the physician’s well-being of 
the doctor-patient relationship. Perhaps, in knowing that other surgeons are 
affected and are negatively impacted when “their” patient gets a PJI the 
individual surgeon will not feel as lonely.186 This may lead to a more open 
discussion and awareness among colleagues, which should have a positive 
effect on the surgeon’s well-being. Further, it is of importance to increase the 
education of patients in order to highlight the severity and reality of PJI.  
There are studies reporting on the patient experience of not being taken 
seriously by their doctors when they present with diffuse PJI symptoms.1, 5, 6 
Surgeons were aware of this in our study. A possible reason may be lack of 
knowledge in PJI within the medical profession. This was brought forth during 
the interviews of the current study. Furthermore, another reason to why 
patients feel they are not taken seriously may be surgeon denial. However, 
surgeons witnessed on a change of attitude in the management of PJI where 
Swedish surgeons today seemed less likely to deny PJI.  
Andersson et al. reported that some patients did not regard their doctors as a 
source of support, whereas some did.5 Emotional intelligence has been 
proposed an important factor in the doctor-patient relationship. Previous 
research suggests that orthopaedic surgery residents demonstrate low 
emotional intelligence and that surgeons need further education on this.233 In 
the current study, all surgeons were perceived as emotionally intelligent, both 
in how they managed their own feelings but also in their understanding of the 
patient’s emotions.  
 
  6 DISCUSSION 
85 
Strengths, limitations and methodological considerations 
 
The current study is the first to explore the experiences and the emotional 
impact of PJI in Swedish surgeons. Further it has identified desired 
improvements that may facilitate the management of PJI for the involved 
surgeons (Paper I, Figure 4). These need to be evaluated for their efficacy.  
 
The current study is based on reflections on PJI cases. The negative impact of 
PJI may have become even more pronounced if interviews were conducted in 
connection to a PJI case or if relatively inexperienced surgeons were 
interviewed.186, 228, 231 The study population was purposively selected for its 
diversity to capture as many perspectives as possible. Therefore, we did not 
strive for proportionality to the population of hip and knee arthroplasty 
surgeons in Sweden. However, in Sweden, 19.7% of orthopaedic surgeons are 
female which reflects nicely in our study population (22%). The over-
representation of male surgeons may risk that certain perspectives important to 
female surgeons were not captured. Further, females are more motivated to 
discuss adverse events.234 In our material there were no obvious differences in 
male and female reflections on PJI. This is in accordance with previous 
research on male and female surgeons reflecting on adverse events.186  
 
It is difficult to objectively prove saturation and, in our study, we may have 
come across new perspectives had we continued our data collection. Therefore, 
based on our sample size, we cannot claim that no new perspectives can be 
captured as this is unknown.  
 
In qualitative research there are several concepts of which trustworthiness can 
be discussed. According to Graneheim et al. trustworthiness is built on 
credibility, dependability and transferability.200 The credibility of a study 
concerns how well data and analysis reflect the study aim. To address this, we 
used purposive sampling and discussed data within our study group of persons 
with different experiences of PJI. Furthermore, the selection of meaning units 
was discussed between AEA and KS to ensure a well-chosen data extraction. 
Quotes from interviewees, translated by a third part, were also intertwined in 
our text. Sending our results to randomly selected study participants was also 
done to confirm credibility. 
 
The dependability of a study addresses how data may change over time, 
perhaps due to data collection stretching over a longer period, or how the 
researcher approaches data during the “maturation” of his or her analytical 
process. In our study, data was collected during a short period of time (3 
months). There was a consistency in KS approach to data and, as mentioned, 
the process of QCA was continuously discussed within the study group.  
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According to Graneheim et al., it is up to the individual reader to assess the 
transferability.200 Cultural and health care organizational differences may limit 
the transferability of our study. The impact on surgeons may be different in 
countries where surgeons may face lawsuits following adverse events.235 We 
believe that our results can transfer to other systems and cultures similar to 
Sweden, i.e. Northern Europe. This is strengthened by the fact that, despite 
differences in both culture and health care systems, our study findings are 
largely consistent with the UK-based study conducted by Mallon et al.177  
 
Clinical implications 
 
The results of this study will most probably not have a direct effect on 
treatment outcomes. However, hopefully it will put light on the importance of 
discussions, sharing experiences and knowledge on PJI between colleagues. 
Doing so should not only create a sense of support for the individual surgeon 
but may also serve as a base for education. Knowing that surgeons find it 
important to work in teams may improve, coordinate or standardize care 
models, which in turn may lead to a positive effect on both treatment outcome 
and health care economics. Previous studies claim that a multi-disciplinary 
approach is necessary for improved treatment outcome,236 and in regard of 
surgeon well-being health care organizations should consider regular 
debriefing possibilities for their staff.   
6.5 GENERAL DISCUSSION   
 
Selection of patients for primary arthroplasty 
 
Surgeons reported on being more restrictive in their selection of patients for 
primary arthroplasty after managing PJI cases (Paper IV). This was not 
explored further, but the correct selection of patients may in theory be an 
important preventive measure for PJI. Many risk factors have been identified 
(page 11) and it is recommended that these should be considered carefully prior 
to primary arthroplasty.28, 237  
 
Further research is warranted to evaluate the effect of optimization of 
modifiable risk factors and how the selection of patients may influence PJI 
incidence to further elucidate the importance of patient-related risk factors. 
Also, the astounding lack of evidence in perioperative factors such as airflow 
and perioperative disinfectants needs to be addressed in further evaluation.  
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Diagnosing PJI 
Surgeons felt that the diagnostics could be difficult and that diagnostic tests 
were unreliable (Paper IV). Intra-operative cultures were considered the 
ultimate proof of infection (Paper IV), and in Paper II, 143 (18%) patients 
were excluded from the analysis due to negative culture growth. 
Considering the proportion of patients with negative growth in Paper II, 
there is a likelihood that some patients in Paper III were culture-
negative. Another study on revisions due to PJI identified culture-negative 
samples in 41% of PJI cases.144 On the other hand, negative culture growth 
does not rule out the possibility of infection. To increase detection rates, 
sonication,58 polymerase chain reaction (PCR),238 or whole-genome 
sequencing can be used. Further, storage and transportation of samples 
may impact culture growth. Another important factor is the use of 
antimicrobials prior to surgery. It is important to establish routines in how 
negative cultures should be managed to facilitate diagnostics. Surgeons 
desired better diagnostic tools, introduced in an evidence-based manner 
(Paper IV), and such a tool may be the use of biofilm measurements 
and MBEC susceptibility testing (Paper I).54   
Although not a diagnostic tool confirming PJI, the use of biofilm production 
measurement, and perhaps MBEC, may aid the surgeons and ID specialists in 
their treatment decisions. This has also been suggested by Saeed et al.54 As 
the presence of strong biofilm producing staphylococci was associated 
with infection recurrence (Paper I), the introduction of biofilm OD 
measurements in routine clinical practice may influence treatment setups. 
Confirmation of a strong biofilm producing bacteria may suggest that 
surgical treatment need be more “aggressive”. This needs further evaluation.
Considering preferences and patient risk factors in the treatment setup 
In this thesis none of the studies focused on the patient perspective, which is a 
weakness, but beyond the scope of this thesis. However, there are 
both qualitative and quantitative studies available on patient experiences 
and physical function after PJI treatment. Hence, in Paper IV we asked 
surgeons on their take on the patient experience. Surgeons agreed upon the 
importance of involving their patient in treatment decisions. Shared 
decision-making may alleviate the surgeon from feeling full 
responsibility and coheres with person centred care. 
It is unknown to what extent patient risk factors affect treatment outcome in 
reoperations due to PJI. Kheir et al. found that previous DAIR, 
previous myocardial infarction or revision surgery were the three most 
important risk factors for failed reoperation due to PJI.239 Previous surgery 
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has been reported a risk facture for failed treatment in other 
studies.224, 240 In Paper II, no patient risk factors could be identified in regard 
of treatment failure when using either DAIR method. However, this 
study only included primary arthroplasties, and neither Paper II 
or III evaluated myocardial disease. The conclusion of Paper II and 
III is that further research is warranted to establish which patient factors 
may make a patient eligible to one or another surgical treatment.  
Microbial factors 
Polymicrobial infections have been associated with a higher failure rate after 
DAIR.38 This was not confirmed in Paper II. However, in this study we did 
not have access to the antibiogram of the causative agents and therefore there 
may have been an under-reporting on the number of polymicrobial infections 
considering intra-species variations. In Paper I, 31% cases were 
polymicrobial, but interestingly there was a greater number of polymicrobial 
cases in cured infections (36%) compared to recurrent infections (25%). 
Previous research has shown that there is a higher risk of failure after DAIR in 
cases where many culture results are positive.38, 154 Tornero et al. discuss the 
possibility that many positive cultures may imply a higher infectious dose and 
thereby cause a more aggressive infection.38 We did not study this in Paper I, 
since the starting bacterial inoculum added to the CBD and microtiter plate test 
was the same for all the strains, and then they exhibited their different biofilm 
production abilities on the plastic surfaces.  
Surgical treatment 
For DAIR, the results of Paper II support an exchange of modular 
components, and coheres with previous research. To date, it is suggested that 
the removal of modular components means better chances of biofilm 
eradication, and in turn better chances for outcome success. However, there is 
no study confirming this. Scanning electron microscopy has confirmed biofilm 
growth on prosthesis components in vivo.52 The components of a hip prosthesis 
in patients with PJI have been examined and it is reported that adherence of 
bacteria is greatest on the polyethylene liners.241 The removal of components 
should therefore theoretically imply a more extensive clean-out. In turn, the 
extraction of a prosthesis performed during one- or two-stage surgery implies 
an even greater chance of biofilm eradication, which may be why these 
methods are superior to DAIR in terms of infection resolution.  
The importance of biofilm eradication for successful treatment outcome is 
further supported by Paper I. In addition to the greater risk of infection 
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recurrence in infections caused by strong biofilm producers, infection relapses 
were more common in patients treated with implant preserving surgery (5 of 6 
relapses, 83%). However, the sample size of relapses was small and therefore 
conclusions should be drawn with caution. Nonetheless, relapses highlight the 
importance of meticulous surgery regardless of whether patients are treated 
with implant preserving or implant extracting procedures.  
Another study on growth of S. aureus in stage one and stage two of two-stage 
surgery reported on relapses of S. aureus in 7.5% of cases and observed a 
greater resistance, measured in increases of MIC, in strains cultured from stage 
two.164 These results underline both the importance of meticulous surgery 
during stage one in terms of a persisting species, and also that bacteria 
exposed to antimicrobial agents may pick up resistance genes. In 
patients where bacteria have not been completely eradicated during 
treatment, there is a risk that they persist as asymptomatic biofilm or as 
small colony variants inside other cells.242  
Antimicrobial treatment 
In Paper II, 39% of patients had received antimicrobial therapy prior to their 
DAIR procedure. Due to the efforts to increase awareness of PJI management 
(Paper IV), this number would perhaps be different if the study were to be 
conducted on patients later than 2009-2015.  
Translational research 
In vitro models aim to mimic in vivo conditions, however, there are several 
interactions that cannot be reproduced in vitro that may have a significant 
influence on clinical presentation and outcome. The CBD model used in 
Paper I does not mirror the surface properties of a prosthetic implant or human 
tissue. Neither does the model consider the nutritional environment of the 
implant interface or the interactions with the host immune system.  
Power problem 
Due to their multi-factorial nature, and relatively low incidence rate, large 
datasets are desired when studying PJI. The ideal studies are prospective, 
multi-centred studies consisting of large study cohorts. This requires 
nationwide and, or, international collaborations in study setups. Another 
alternative to address the power problem is conducting individual participant 
data pooled analyses or using the national joint registers.  
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Infections in the national registers 
Several register-based studies have been performed to analyse different 
aspects of PJI. Revision rates, incidence rates, surgical procedures and risk 
factors have been studied in national datasets 19, 22, 82, 243-245. However, 
infections are of a multi-factorial character and currently, national joint 
registries alone do not provide adequate data for a comprehensive approach 
to infection research.227 The inconsistency in data collection and definitions 
of infection in the registers further aggravate comparisons of PJI within 
registers. Infection burden has also been suggested to be underestimated in 
national joint registers. 4, 14 
In the registers, infections are reported  as revision procedures. It is therefore 
important to mention that patients with infections who are not subject 
to revision or other reoperations are not captured within the registers. Further, 
the definition of infection is inconsistent across the registers, and revision can 
be defined as all procedures manipulating, exchanging, or removing 
prosthesis parts. Some registers categorize the procedures and report 
on them accordingly, others do not make distinctions between the 
procedures.  
The registers report on completeness of registered data in their annual reports 
but not specifically on completeness of reported infection procedures. 
Validation of data reported on infection to the registries is important in order 
to maintain a high data quality. Validation studies of the Danish and Swedish 
arthroplasty registers have shown an under reporting of PJI. 226, 246 Gundtoft 
et al. calculated the incidence of PJI using the Danish National 
Arthroplasty Register (DHR)  reported that the incidence of PJI was 40% 
lower using the DHR compared to their algorithm based on multiple 
sources.247 An underestimation of the incidence of PJI has also been 
suggested in the Finnish Arthroplasty Register.17  
Studies reviewing the sensitivity in capturing reoperations for PJI and 
capturing PJI are presented in Table 6. Definitions of time period for 
incidence rates or reoperation rates vary for the studies. Minor wound 
revisions and salvage procedures risk not being registered, and 
implant preserving reoperations risk not being reported or may be omitted in 
the register. 4, 14, 248 
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Table 6. Studies on the capture rate of PJI in national joint registers. 
 
Study Register Reoperation rate 
in register 
Reoperation rate 
from other source 
Register 
sensitivity 
Zhu et al.14 New Zeeland 
Joint Register 
0.67% 1.07% (hospital 
discharge records) 
63% 
Jämsen et al.4 Finnish Knee 
Register 
0.77% 0.89% (Finnish 
Patient Register) 
87% 
Lindgren et 
al.226 
The Swedish Hip 
Arthroplasty 
Register 
1.30% (Swedish Prescribed 
Drug Register) 
67% 
Gundtoft et 
al.249 
The Danish 
Arthroplasty 
Register 
Not stated National Register of 
Patients, medical 
records* 
67% 
*and supplementary information from prescription, microbiology and biochemistry databases 
 
The national registers have an enormous strength in that they provide an 
opportunity to conduct research on big populations. This is crucial to be able 
to monitor infections, study incidence rates, changes in incidence rates and 
surveil trends in which further scientific studies should be performed to 
validate and explain the register findings. 
 
Addressing the limitations in national joint registries 
 
It may be difficult to reach consensus on how to report on infections within 
registers. It is important to be able to compare annual statistics within a register 
and therefore it may be difficult to change current definitions. However, a 
harmonization of reporting would facilitate international comparisons and 
collaboration studies across the registers. Therefore, there is a need to agree 
upon certain variables of infection interest that are adopted into all registers.  
 
In the meantime, collaborative studies using register linking may be an 
alternative to obtain necessary data. This method has been adopted by Gundtoft 
et al. as Denmark offers a unique possibility for supplement on microbial 
growth via their national microbiological register.249 Holmberg et al. collected 
medical records to retrieve pathogenic information and this method was also 
employed in Paper II.250  
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Table 6. Studies on the capture rate of PJI in national joint registers. 
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7 CONCLUSIONS 
• Paper I Patients infected by strong biofilm producing 
staphylococci have up to 5 times greater risk recurrent 
infection than when infected by non/weak producers. Biofilm 
measurements should be considered in routine clinical 
practice as the presence of strong biofilm producing bacteria 
may indicate the need for more aggressive surgical therapy.
• Paper II Using DAIR with the exchange of modular 
components results in reduced risk of further reoperations due 
to infection and should be employed in all patients eligible for 
DAIR.
• Paper III The risk for re-revision is similar for the one- and 
two-stage procedure. This supports the use of the one-stage 
method, but needs further evaluation in future studies.
• Paper IV Prosthetic joint surgeons experience a negative 
emotional impact when managing PJI. Facilitating factors 
such as peer support and multidisciplinary approaches were 
identified as the most important coping strategy. The current 
study reports on further improvements desired by surgeons 
working with PJI. The results and suggestions on 
improvement may transfer onto surgeons in other medical 
fields managing postoperative infections.
• A multidisciplinary approach in research and clinical 
management are necessary factors for future progress in the 
treatment of PJI (Paper I and Paper IV). This has been 
brought forth in previous publications, and may also be true 
for other orthopaedic infections, or medical device-related 
infections in general.
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Figure 27.  Multidisciplinary team from multiple disciplines working together to 
discuss clinical cases and collaborative research work. From the left: clinical 
microbiologist, ID specialist, orthopaedic surgeon 1, orthopaedic surgeon 2, 
experienced prosthetic joint surgeon 1, experienced prosthetic joint surgeon 2, 
microbiologist and biomaterial researcher. 
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8 FUTURE STUDIES AND 
PERSPECTIVES 
 
The current studies have led to new research questions, planned add-on work 
and further projects.  
 
Paper I 
• The current study was limited to first-time infection of total 
arthroplasty of the hip or knee. Staphylococci from 
reoperations due to infection of other orthopaedic implants 
(hemi-arthroplasties) and not limited to first-time infections 
have also been analysed. In addition, molecular 
microbiological analyses of the strains were performed and 
this additional data will be compared to clinical outcome 
(infection resolution/recurrence).  
• A prospective study is under planning to evaluate whether 
MBEC can be used as a surrogate marker for biofilm 
susceptibility in a clinical setting.  
 
Paper II  
• The database created for Paper II offers a unique opportunity 
to further evaluate different aspects of the DAIR procedure. 
We are in the process of merging it with the Swedish Drug 
Database (Läkemedelsregister) to obtain a more accurate 
outcome parameter and to improve our analysis of optimum 
treatment for infection resolution.  
• Delayed wound closure was used at some orthopaedic units 
during the study period. A study on evaluating the success 
rates of this surgical method in terms of further reoperations 
or revision surgery is planned. 
 
Paper III 
• The research group is involved in a prospective randomised 
controlled trial in a multi-centre setting which was initiated 
and set up by the INFORM group.151 This study is the first of 
its kind to investigate whether there is a superiority in either 
the one- or two-stage method, but with focus on patient 
reported outcome measures. Data analysis is in process and 
the manuscript is planned for submission in 2020.  
 
 8 FUTURE STUDIES AND PERSPECTIVES 
95 
 
In general, much can be done to improve the research possibilities within, and 
management of, orthopaedic infections. Some of the current limitations have 
been mentioned in this thesis including the difficulties in conducting 
comprehensive infection research using national joint registers and the 
difficulties in translational research.  
 
• There is a need to further establish the mechanisms of 
pathogenesis in orthopaedic infections. Acquiring a greater 
knowledge on the mechanisms of pathogenicity is essential to 
generate new treatment alternatives. Several basic 
improvements that may facilitate research on pathogenic 
factors could be to establish routines for the management of 
intra-operative samples.  
• In regard of biofilm, there is a need to develop clinical 
breakpoints for susceptibility testing of antimicrobial agents 
on biofilms. Further, developing clinically available 
techniques for establishing the presence, and pathogenicity, 
of biofilms using surrogate markers or imaging techniques is 
warranted.  
• It is important to evaluate whether the virulence properties of 
microorganisms can be associated to biomarkers as this 
would facilitate the diagnosis and further management of PJI.  
• The influence of patient factors needs to be further studied in 
order to improve the selection of patients for arthroplasty 
surgery and to identify whether patient factors impact the 
treatment of PJI. 
• There is a need to establish a standardized way of reporting 
on PJI with defined outcome measures in order to increase 
comparability and improve the possibilities of metanalyses  
and register-based research to increase study populations. 
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Supplementary Table 1. The EUCAST definitions on breakpoints for staphylococci and the 
antimicrobials tested in the study.133 
Antimicrobial agent MIC breakpoints (mg/L) 
S £ R> 
Ciprofloxacin S. aureus
CoNS
0.001 
0.001 
1 
1 
Clindamycin 0.25 0.25 
Fusidic acid 1 1 
Linezolid 4 4 
Oxacillin S. aureus
CoNS
2 
0.25 
2 
0.25 
Rifampicin 0.06 0.5 
Trimethoprim/sulfamethoxazole 2 4 
Vancomycin S. aureus
CoNS
2 
4 
2 
4 
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Supplementary Figure 1. The report form that was sent out for supplementary on infection 
data on a patient level to all orthopaedic units in Sweden. 
 
 
 
 
 
 
 
Social security number 
  
Date of reoperation 
(year-month-day)  
Reoperation due to infection 
Sequence number according to SHAR 
 
Number of culture samples 
How many samples were obtained during 
the arthrocentesis/operation?  
 
Preoperative: 
 
Peroperative: 
Number of positive samples for each 
microbe 
e.g.: 3 staphylococcus aureus, 2 CoNS 
 
Preoperative: 
 
Peroperative: 
Onset of symptoms 
When did the patient contact health care 
for the first time? (year-month-day) If the 
date is unclear, please state month and 
year (e.g. 2015-10-?) 
 
   
Antimicrobials prior to surgery? 
 (yes/no) 
 
Antimicrobial agent 1 
Which type(s) of intravenous 
antimicrobials did the patient receive? 
 
Antimicrobial agent 2 
Which type(s) of antimicrobial agents 
were prescribed at discharge? 
 
Change of antimicrobial agents 
Was the antimicrobial therapy changed 
after discharge? 
 
Duration of antimicrobial therapy 
How long did the patients receive 
antimicrobial treatment? Choose the best 
alternative.  
 
 < 4 v          4 – 8 v          8 – 12 v           > 12 v 
Additional comments  
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Supplementary Figure 2. The protocol used as a topic guide list for the interviews conducted 
in Paper IV. 
 
Semi-structured protocol 
The interview starts off with brief information about the interview setup and that the audio-
records and interviews are stored unidentified and that no one outside of the study group 
can access them. Participants are asked once again to consent to their partaking in the study. 
 
Aim: To acquire an understanding for how orthopaedic surgeons perceive and experience 
the management of PJI, the emotional impact of it and identify areas of improvement. 
 
• What experience do you have of revision surgery due to PJI of the hip? 
• How many years have you worked with PJI of the hip? 
• Do you have a method of preference (one- or two stage revision) and if so, why? 
• Which difficulties do you encounter in managing deep PJI? 
• Do you feel that there are any difficulties in the diagnostics of PJI, if so, what are 
they? 
• Which difficulties do you encounter when setting up a treatment plan? 
• How do you reason when planning treatment? 
• How do you feel about choosing a treatment plan? 
• Which patient factors may make you prone to choosing one treatment alternative 
rather than another? 
• Which are the strengths/weaknesses in current care and management of PJI 
patients? 
• How does the patient group affect you emotionally? 
• How is it to meet patients with PJI, how does it affect you? 
• How does it affect you when one of your patients gets a PJI? 
• How do you manage the difficulties you encounter when managing PJI? 
• Do you receive any support, and if so, what type? 
• Is there any type of support you and your colleagues may need? 
• What do you think is a good means of support? 
• Based on your experiences, which aspects of management and care of PJI patients 
need improvement? 
• Which are your suggestions to facilitating the management of PJI? 
• Can you see any specific areas of management, care and organization that imply a 
threat to the patient’s security? 
• Which improvements have contributed to improved diagnostics and eased 
management of PJI during your career? 
• How do you keep yourself updated on PJI management? 
• What do you think are the most important factors to facilitate the patient 
experience of PJI? 
• Is there anything you would like to add or anything else you think we should 
cover? 
 
 
 
 
 
 APPENDIX 
126 
Supplementary Figure 1. The report form that was sent out for supplementary on infection 
data on a patient level to all orthopaedic units in Sweden. 
 
 
 
 
 
 
 
Social security number 
  
Date of reoperation 
(year-month-day)  
Reoperation due to infection 
Sequence number according to SHAR 
 
Number of culture samples 
How many samples were obtained during 
the arthrocentesis/operation?  
 
Preoperative: 
 
Peroperative: 
Number of positive samples for each 
microbe 
e.g.: 3 staphylococcus aureus, 2 CoNS 
 
Preoperative: 
 
Peroperative: 
Onset of symptoms 
When did the patient contact health care 
for the first time? (year-month-day) If the 
date is unclear, please state month and 
year (e.g. 2015-10-?) 
 
   
Antimicrobials prior to surgery? 
 (yes/no) 
 
Antimicrobial agent 1 
Which type(s) of intravenous 
antimicrobials did the patient receive? 
 
Antimicrobial agent 2 
Which type(s) of antimicrobial agents 
were prescribed at discharge? 
 
Change of antimicrobial agents 
Was the antimicrobial therapy changed 
after discharge? 
 
Duration of antimicrobial therapy 
How long did the patients receive 
antimicrobial treatment? Choose the best 
alternative.  
 
 < 4 v          4 – 8 v          8 – 12 v           > 12 v 
Additional comments  
 APPENDIX 
127 
Supplementary Figure 2. The protocol used as a topic guide list for the interviews conducted 
in Paper IV. 
 
Semi-structured protocol 
The interview starts off with brief information about the interview setup and that the audio-
records and interviews are stored unidentified and that no one outside of the study group 
can access them. Participants are asked once again to consent to their partaking in the study. 
 
Aim: To acquire an understanding for how orthopaedic surgeons perceive and experience 
the management of PJI, the emotional impact of it and identify areas of improvement. 
 
• What experience do you have of revision surgery due to PJI of the hip? 
• How many years have you worked with PJI of the hip? 
• Do you have a method of preference (one- or two stage revision) and if so, why? 
• Which difficulties do you encounter in managing deep PJI? 
• Do you feel that there are any difficulties in the diagnostics of PJI, if so, what are 
they? 
• Which difficulties do you encounter when setting up a treatment plan? 
• How do you reason when planning treatment? 
• How do you feel about choosing a treatment plan? 
• Which patient factors may make you prone to choosing one treatment alternative 
rather than another? 
• Which are the strengths/weaknesses in current care and management of PJI 
patients? 
• How does the patient group affect you emotionally? 
• How is it to meet patients with PJI, how does it affect you? 
• How does it affect you when one of your patients gets a PJI? 
• How do you manage the difficulties you encounter when managing PJI? 
• Do you receive any support, and if so, what type? 
• Is there any type of support you and your colleagues may need? 
• What do you think is a good means of support? 
• Based on your experiences, which aspects of management and care of PJI patients 
need improvement? 
• Which are your suggestions to facilitating the management of PJI? 
• Can you see any specific areas of management, care and organization that imply a 
threat to the patient’s security? 
• Which improvements have contributed to improved diagnostics and eased 
management of PJI during your career? 
• How do you keep yourself updated on PJI management? 
• What do you think are the most important factors to facilitate the patient 
experience of PJI? 
• Is there anything you would like to add or anything else you think we should 
cover? 
 
 
 
 
 
